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ABSTRACT OF DISSERTATION

ON T CELL FATE DECISIONS: RETINOL, METABOLISM AND ITREG
DIFFERENTIATION
The mammalian immune system is equipped to both eliminate pathogenic
microorganisms and tumors, while remaining in homeostasis with commensal species at
mucosal surfaces and tolerant towards self. Suppressor regulatory T cells (Tregs) are a
major sentinel of this immunological tolerance. Induced Tregs (iTregs) arise in the
periphery following the integration of cues from the metabolites, cytokines, etc. which
make up its milieu. Dysregulation of iTreg development, function or homing underlies
the etiology of many autoimmune diseases and immunopathologies. The amelioration or
prevention of multiple murine disease models by boosting Treg cell numbers
foreshadows clinical efficacy of iTreg therapy, but an incomplete understanding of Treg
development has thus far prevented successful translation. Therefore, we considered the
basic biology of T cell fate decision making from two unique, but integrated angles. First,
we show that the stimulation of PPARγ in human T cells upregulates RDH10, a molecule
which catalyzes the rate limiting step in the oxidation of retinol to transcriptionally active
all-trans retinoic acid (ATRA), a positive regulator of iTreg development. This
functionally intact pathway endows T cells the ability to autonomously sense and respond
to retinoid signals present during Treg development and at tissue sites. Next, we asked
questions about how T cells sense nutrient and oxygen availability as they differentiate.
Tregs lacking the serine/threonine kinase PINK1 have limited activation-induced
phosphorylation of Akt and oxidative phosphorylation rates, and reduced suppressor
function. Notably, the uncoupling of iTreg function from normal FoxP3 expression
reinforces the recent hypothesis that the PI3K/Akt/mTORC1 axis and metabolic
checkpoints are decisive players in the acquisition of suppressor activity. Ultimately, the
studies described herein converge on Akt and metabolism, and contribute to our
understanding of how T cells integrate diverse signals present during fate determinism,
provoking future Treg based therapeutics.
Keywords: Tregs, PPARγ, IBD, Metabolism, Akt
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Chapter 1: Introduction
1.1

The “problem” of immunity
There was a brief moment in history after the origin of life, but before the first

cell division, where the first single celled organism existed in complete singularity and
immunity didn’t exist; it didn’t need to. Reproduction begot speciation, speciation created
competition and competition necessitated the development of a defense system which
would become immunity. The proto-immune system acted to degrade foreign nucleic
acids, followed by the development of innate immunity in eukaryotes – quick, but only
able to recognize patterns of molecules commonly found on pathogens, and without the
ability to finger repeat offenders. Ever-increasing organismal complexity and the
evolution of novel and diverse forms of invasion commanded the development of the
adaptive immune system, originally seen in the gnathostome superclass of jawed
vertebrates. The ideal immune system would quash invaders before having a chance to
expand in number, yet retain adequate specificity and to be able to respond to an
unlimited array of antigens.
Adaptive immunity is bifurcated into cell-mediated and humoral immunity, the T
and B lymphocytes, respectively. T cells have diverse functions within the immune
system, but generally kill infected or aberrant cells, activate complementary arms of the
immune system including antibody secretion from B cells or suppress inappropriate proinflammatory responses. A T cell’s specificity is encoded within its T cell receptor
(TCR), which is uniquely and randomly rearranged during T cell development. The
crosslinking of the TCR by cognate peptide presented by antigen presenting cells (APCs)
drives the activation and expansion process of clonal expansion. TCR gene
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rearrangement during T cell development has the capacity to generate an unlimited
number of dissimilar TCRs. Herein lies the problem of immunity: to ensure no pathogen
goes undetected, the process of TCR diversification must produce T cells which
recognize self, benign or beneficial antigens, resulting in autoimmunity, allergy and
immunopathogenesis. Immunological tolerance became the solution.
1.2

Immunological tolerance: the solution to the problem
After egress from the bone marrow, pluripotent hematopoietic stem cells populate

the thymus, where Notch1 signaling from stromal cells commits them to the T cell
lineage, and incites TCR rearrangement and expression of both the CD4 and CD8 coreceptors. Education of T cells to ensure tolerance occurs almost immediately. These
“double positive” (DP) cells interact with self-peptide:self-major histocompatibility
complex (MHC) in the thymic cortex and undergo positive selection by integrating TCR
and co-receptor signals. DP cells that cannot bind to and signal through CD4 or CD8 will
undergo apoptotic death by neglect, whereas successful signaling provides a proliferation
signal, upregulates TCR expression and downregulates expression of the unused coreceptor, leaving either a single positive (SP) CD4+ or CD8+ lymphocyte depending on
the class of MHC encountered; this dissertation will focus on CD4+ T cells. Negative
selection occurs next: SP T cells interact with medullary thymic epithelial cells
expressing an array of self-peptides under the control of the autoimmune regulator, Aire.
Cellular fate at this juncture is determined by the strength of the signal: T cells which
react too strongly to self-peptide are destined for apoptosis, as they may cause
autoimmunity, intermediate binding results in the development of anti-inflammatory
natural regulatory T cells (nTregs) and the remaining cells leave the thymus as mature,
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naïve T cells. A full 98% of thymocytes do not survive T cell development, but the 2%
that do are fully-armed cells that have the ability to recognize and respond to any
protein:MHC complex that later binds faithfully. Notably, the intertwining of tolerance
and T cell maturation is a testament to the commitment of the immune system to the
prevention of autoimmunity, and represents the first stage at which the integration of
signals helps determine T cell fate.
Upon egress from the thymus, naïve CD4+ T cells are on constant lookout for
cognate antigen presented by APCs in the context of MHC class II molecules. Since most
T cells with self-reactive TCRs are deleted during the negative selection phase of thymic
development, the majority of T cells search for foreign antigens. The odds of a productive
T cell:APC event in peripheral blood is quite low, so naïve T cells traffic to leukocyterich secondary lymphoid organs such as lymph nodes, spleen and mucosal associated
lymphoid tissue, including Peyer’s patches in the gut. After entering one such organ, a T
cell will interact with thousands of dendritic cells (DCs) per day, sampling the buffet of
peptide:MHC complexes on the surface of the APCs. The vast majority of these
interactions will be brief – only lasting seconds to minutes on average – before a T cell
moves on to the next APC, ultimately ending up back in the blood if nothing piques its
interest. On rare occasions, a T cell will suitably bind to an APC with enough affinity that
TCR signaling will stabilize the interaction. Additional co-stimulatory signals are
provided by molecules like CD28, which initiate the cell cycle, interleukin-2 (IL-2)
secretion and expression of the α-chain of the IL-2 receptor, CD25. TCR activation of
naïve T cells in the absence of CD28 co-stimulation induces T cell anergy, and is another
mechanism of tolerance. It is during TCR stimulation that activation, clonal expansion
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and T cell effector fate decision making occurs based on integration of the signals
received from a cell’s local microenvironment.
Though organismal complexity has increased via an evolutionary random walk
away from the simplest forms of life, bacteria, viruses and other single-celled
microorganisms are to this day the modal organisms on this planet, and with this
abundance comes diversity1. Organisms have evolved to infect, grow, persist and
reproduce in every available tissue niche in the human body, and the most successful of
pathogens subvert, depress, hoodwink or misdirect the human immune system: HIV hides
out in CD4+ T cells and integrates its genetic information into the host genome,
Trypanosoma brucei drastically changes its variant surface glycoprotein coat, etc.
Therefore, the immune system must tailor its response to fit the pathogen encountered
and the body site in which it is found. Part of this adaptation involves the orchestration of
distinct CD4+ T cell subsets. A T cell undergoing activation acquires its homing
specificity and cytokine secretion profile depending on the signals it receives from the
environment. Though initially thought to be distinct and immutable, CD4+ T cell subsets
in vivo are actually variegated and plastic – CD4+ T cells can exhibit characteristics of
multiple subsets and can re-differentiate into a new subset based on subsequent
microenvironmental signals2. In general, pro-inflammatory CD4+ T cells are classified
into three subsets: Th1, Th2 and Th17. The cytokine signals, master transcription factors
and signature cytokine secretion profiles of each of the major subsets are listed in Figure
1.1, in addition to their primary functions. Improper T helper responses can not only be
ineffective, but also pathogenic. For example, initiating a Th2 response against
Mycobacterium leprae will allow it to persist inside macrophages and cause lepromatous
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leprosy3, and Th1-mediated inflammation in the brain could cause damage due to
swelling within the enclosed cranium and induced cell death of a non-replicating cell
type.
In contrast to the pro-inflammatory response, some T cells become induced Tregs
(iTregs), an anti-inflammatory subset of CD4+ T cells instructed to develop by the
coordinated action of the cytokines transforming growth factor-β (TGF-β) and IL-2. Like
their nTreg counterparts, iTregs develop following the induction of its master
transcriptional regulator, FoxP34, and in humans, can be identified by their high
expression of CD255, CTLA-46, GITR7 and low expression of CD1278. Though nTregs
and iTregs have yet to be assigned distinct physiological roles, Helios is a zinc-finger
protein expressed by nTregs, but not by iTregs9, and the conserved noncoding sequence 1
(CNS1) region of Foxp3 contains binding sites essential for iTreg development, but
dispensable for nTregs10. Contemporary opinion supposes that these etiological
differences between nTregs and iTregs contribute to their distinct TCR repertoires, and
assigns separate, but still overlapping regulatory roles in the control of inflammation11;
nTregs were hypothesized to tolerize towards self antigens12, while iTregs filled the nonself niche13. However, these roles are still being experimentally defined, and single-cell
sequencing indicates that the majority of Tregs are thymus derived, including those in the
colon, which is replete with non-self antigens14. Though tolerance via nTreg activity may
be sufficient in young individuals with large thymi, thymic involution decreases output of
all T cells including nTregs, suggesting a continuing role for iTregs later in life15, and
ablation of iTregs results in Th2-type immunopathogenesis at mucosal surfaces16.
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FoxP3 itself binds to DNA at its consensus sequence17 where it acts as a
transcriptional repressor. Cytokine genes are a major target of FoxP3, which reduces the
secretion of IL-4, interferon-γ (IFN-γ) and the IL-2 which supports its development and
stability18. Though it holds true in mice, the discovery of FoxP3- Tregs and FoxP3+ cells
lacking suppressor function19,20 has shown FoxP3 to be neither necessity nor sufficient
for human iTreg development. Tregs suppress through several cell contact dependent and
independent mechanisms (Figure 1.2), and results in multiple anti-inflammatory
outcomes including reduced proliferation, differentiation and cytokine secretion of
bystander immune cells. It is a key feature of Tregs that they are activated in an antigenspecific manner, but suppress non-specifically. In addition, Tregs can impart infectious
tolerance by manipulating the T cell microenvironment to such that fosters
immunosuppression21; adoptive transfer of congenically marked Tregs to non-obese
diabetic mice prevented pathology despite their transient persistence. Instead, newly
generated, marker-negative Tregs assumed the responsibility of reinforcing tolerance and
preventing a diabetic state22.
The contribution of FoxP3 and Tregs towards tolerance was recognized upon the
creation of hemizygous “scurfy” mice carrying a mutated FoxP3 lacking its forkhead
domain, which succumb to a lymphoproliferative disease marked by multi-system
autoimmunity23. Concordant symptoms were seen in humans diagnosed with immune
dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), leading to
the identification of multiple loss-of-function mutations in FoxP3 as the causative agent
of disease24. Since this initial characterization, several autoimmune diseases have
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likewise been at least partially attributed to dysregulation of Treg-mediated
immunosuppression22,25–28.

1.3

Treg control of intestinal homeostasis
Nowhere is tolerance more relevant than in the over 400 square meters of

gastrointestinal tract that houses 1014 microbial residents at a density of up to 1012
organisms per cubic centimeter. Because food and nutrients must be absorbed through the
gut wall, the epithelial cell layer separating the underlying immune cells of the lamina
propria from the gut lumen is only a single cell thick, seemingly setting the stage for
uncontrolled inflammation directed against enteric bacteria. However, there exists a
panoply of mechanisms which ensure peaceful co-habitation between the body and the
microbiota, which is clearly illustrated by the number and diversity of mouse models that
cause intestinal inflammation. Administration of dextran sodium sulfate (DSS) to
drinking water abrades the epithelial cell layer, causing an innate form of colitis that
occurs even in SCID mice lacking adaptive immune cells. In the T cell transfer model of
colitis, the transfer of Treg-depleted CD4+ T cells into an immunocompromised host
causes intestinal inflammation29. Colitis can also be initiated by particularly invasive
bacterial species30 or genetic ablation of vital anti-inflammatory molecules, as in the case
of the IL-10 knockout mouse31. For many of these models, mucosal inflammation only
occurs when mice are housed inside a conventional animal facility that is permissive of
the establishment of a gut microbiota31 and can be ameliorated by antibiotic treatment32,
exhibiting specificity of the response.
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In addition, the human gut experiences an estimated 10-15 kilograms of non-self
proteins per year from dietary sources. Loss of tolerance towards these antigens is the
basis of many food allergies and pathologies like celiac disease, an inappropriate
inflammatory reaction against gluten. Aside from the symptoms of abdominal pain and
cramping, intestinal inflammation reduces the ability to absorb fat soluble vitamins,
calcium or other nutrients from food sources. Immunological homeostasis with ingested
antigens is established by mechanisms of oral tolerance, and is not restricted to food
antigens. CD4+ T cells from mice fed myelin basic protein can ameliorate experimental
autoimmune encephalomyelitis directed against this antigen in part by TGF-β
production33, and the ingestion of poison ivy has been a strategy long-since employed by
Native Americans to combat urushiol-induced contact dermatitis34. In a model of
ovalbumin feeding, antigen specific FoxP3+ regulatory T cells were efficiently generated
in the mesenteric lymph nodes (MLN), lamina propria and Peyer’s patches following oral
administration35.
The lack of sterility found at mucosal surfaces necessitated a specialized immune
system that reacts differently than that of the rest of the body. Though the immune system
must tolerate commensal and food antigens, it must be able to identify and eliminate
enteric pathogens, and permit extra-mucosal immunity against commensals to persist in
the case of bacterial invasion. Dynamic, low level inflammation keeps bacterial
symbionts in check via tightly regulated homeostasis between lymphocytes including
activated and regulatory T cells – non-activated T cells are not often found in the
intestine. To achieve this goal, three-quarters of all lymphocytes are located within the
mucosal immune system, and mucosal B cells produce between 3 and 5 grams of
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immunoglobulin A per day. Within the intestine, T cell activation occurs in the gutassociated lymphoid tissue, organized lymphoid regions including Peyer’s patches which
drain via lymphatics to the MLN. Dendritic cells in the lamina propria extend their
processes between epithelial cell tight junctions36 to sample luminal antigens, while those
in Peyer’s patches have direct access through microfold cells (M cells). Upon antigen
uptake, DCs alter their homing properties and traffic to the MLN where they present
antigen to gut T cells along with instruction for activated T cells to remain within the
mucosal immune system.
In humans, the loss of peripheral tolerance towards commensal bacterial antigens
in the gut leads to the development of Crohn’s disease (CD) or ulcerative colitis,
disorders collectively known as inflammatory bowel diseases (IBDs). Although both
morbidities are often difficult to separate diagnostically, each has its own hallmarks.
Crohn’s disease patients develop non-caseating granulomatous inflammation which can
manifest anywhere in the GI tract, but largely develops in the colon or ileum as
discontinuous “skip lesions”. Inflammation is usually transmural and commonly leads to
fibrotic strictures or fistulae. Crohn’s has classically been considered a Th1 mediated
disease due to expression of the Th1 signature transcription factor, T-bet and increased
secretion of IFN-γ, IL-2, IL-18 and IL-12. However, this paradigm is now in flux, as
many of the disease qualities attributed to IL-12 must now be re-characterized because of
the historical use of antibodies which did not differentiate between IL-12 and the Th17produced IL-23. IL23p19 knockout, but not IL12p35 knockout mice were protected from
disease in a transfer model of colitis37, and monoclonal antibodies directed against
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IL23p19 ameliorate symptoms in a Helicobacter hepaticus model of intestinal
inflammation38.
On the other hand, ulcerative colitis is a continuous, Th2 mediated inflammatory
disease manifesting exclusively in the colon and marked by increased levels of TGF-β
and IL-5. Ulceration of the intestinal wall in colitis is not as deep as is seen in Crohn’s
disease. Although ulcerative colitis can be completely cured by removal of the inflamed
gut region, it is only recommended for patients with excessive blood loss, a high risk of
colon cancer or gastrointestinal perforation39. Despite the number of differences between
the two pathologies, 5-15% of IBDs cannot be classified as Crohn’s or ulcerative colitis
and are termed “indeterminate colitis.”40 Concordantly, several therapies such as
monoclonal antibody neutralization of the Th1 cytokine tumor necrosis factor-α (TNF-α)
have shown efficacy in both Crohn’s disease and ulcerative colitis, demonstrating the
similarity between pathologies41.
Notably, no mouse model of intestinal inflammation fully recapitulates the
clinical features of either Crohn’s disease or ulcerative colitis, underscoring the diversity
of disease in IBD patients due to the equal contributions of genetics, the environment and
the microbiota, and making targeted therapeutics a less viable option for disease
amelioration versus a more general approach. Several mouse models of autoimmune
disease provide proof-of-principle for iTreg based therapies including IBD42, arthritis27
and autoimmune diabetes43. Yet, several key blockades relating to differences in murine
and human T cell biology must be resolved before this approach appears in the clinic.
While FoxP3 is unique to Tregs in wild type mice, human FoxP3 expression can be found
in activated cells without suppressor activity20 and can be lost by Tregs that subsequently
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gain effector function2. Moreover, the large titers of pooled Tregs needed to enact a
therapeutic benefit in mouse models of autoimmunity suggest the same will be true in
human disease, which will require adequate expansion from FoxP3- precursors. Because
of our inability to identify pure populations of human iTregs, the transfer of a sorted
FoxP3+ population of cells would be contaminated by effector cells, exacerbating
symptoms. Therefore, the identification of molecular and genetic signals involved in the
development and expansion of stable, uniquely identifiable Tregs is an active area of
research.
1.4

Signaling an iTreg response
1.4.1

The PI3K/Akt/mTOR axis: a hub of T cell fate determinism

The interaction of a T cell with its appropriate antigen on the surface of an APC is
the first step in the activation of a CD4+ T cell. As part of this process, TCR interaction
with peptide:MHC complexes, CD28 binding to B7 molecules and signaling of IL-2
through its receptor (IL-2R) all activate the phosphoinositide 3-kinase (PI3K) signaling
pathway within seconds, modifying cellular processes to support clonal expansion and
differentiation. Activated PI3K phosphorylates phosphatidylinositol (4,5)-diphosphate
(PI-4,5P2), yielding the PI-3,4,5P3 needed to recruit pleckstrin homology (PH) domain
containing proteins to the inner leaflet of the plasma membrane including the
serine/threonine kinase Akt, a protein at the hub of several pathways controlling host
proliferation, growth, apoptosis, differentiation and metabolism44,45.
Though it was originally recognized for its role in viral oncogenesis46, Figure 1.3
shows the positioning of Akt downstream of receptor tyrosine kinases including the
insulin receptor, TCR and CD28 co-stimulatory receptor . Each of the three isoforms of
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Akt (Akt1, Akt2 and Akt3) is organized into three functional domains. The N-terminal
PH domain endows Akt the ability to bind PI-3,4,5P3, and to a lesser extent PI-3,4P2,
embedded in the cytosolic side of a cell’s plasma membrane. Its central kinase domain
preferentially phosphorylates the protein consensus sequence RXRXX(S/T), which is
controlled by the molecule’s C-terminal regulatory domain.
Activation of Akt begins with a conformational change to reveal two
phosphorylation sites within the regulatory domain. Subsequent phosphorylation of
threonine 308 (T308) by phosphoinositide-dependent kinase-1 (PDK1) and serine 473
(S473) by a yet unknown kinase then activates the kinase activity of Akt. Though Akt
regulates mammalian target of rapamycin (mTOR) via phosphorylation, evidence exists
that mTOR complex 2 (mTORC2), of which mTOR is a member, could be the identity of
one of the kinases responsible for S473 phosphorylation in a reciprocal type of regulatory
relationship47. mTOR, a serine/threonine kinase in its own right, acts as a component of
one of two multi-protein mTORCs. When mTOR conglomerates with several proteins
including raptor and Rheb, mTORC1 has distinct qualities from mTORC2 that includes
rictor, including sensitivity to inhibition by the small molecule rapamycin. Downstream
of Akt, mTORC1 promotes the protein synthesis needed for cell growth and proliferation
by phosphorylating p70 ribosomal S6 kinase 1 (S6K1) to facilitate transcription48 and
eukaryotic initiation factor 4E (eIF4E) to enable cap-dependent translation49.
Downstream effects of the PI3K/Akt/mTOR have a pronounced role during T cell
fate decision making. In mice with a T cell specific deletion of the mTOR gene Frap1,
proliferation was attenuated following CD3/CD28 stimulation, and neither Th1 nor Th2
nor Th17 polarizing conditions were able to impart the ability to produce IFN-γ, IL-4 or
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IL-17, respectively. Instead, stimulated Frap1-/- T cells express FoxP3 and assume
regulatory T cell function, even in response to the Th1-polarizing Vaccinia virus in vivo
50

. In this way, iTregs can be seen as the default differentiation pathway, away from

which mTOR is able to cause deviation. Alternatively, forced constitutive activation of
Akt antagonizes FoxP3 development51.
The type of mTORC activated following TCR stimulation directs effector cell
subset differentiation. In Rheb-/- mice which lack mTORC1 activity but have sufficient
mTORC2, Vaccinia instead provokes the generation of IL-4+ Th2 T cells, and fewer IL17+ cells are found in Peyer’s patches. Conversely, Th2 cells rely on mTORC2; Rictor-/T cells develop into Th1 and Th17 cells, but not Th2 cells. Although the exact
mechanisms by which the PI3K/Akt/mTOR axis works have not yet been elucidated,
cytokine receptor associated signal transducer and activator of transcription (STAT)
proteins have reduced phosphorylation without mTOR expression52.
1.4.2

The minimal iTreg inducers: TGF-β and IL-2

Our lab53 and others have differentiated human iTregs upon culture of stimulated
CD4+ FoxP3- T cells with TGF-β and IL-2. TGF-β is a cytokine with pleiotropic effects
that can vary or even oppose each other based on cell type, activation state or host
species54. Signal transduction begins when TGF-β binds to receptor type II, allowing it to
recruit and phosphorylate receptor type I (TGF-βR1). TGF-βR1 is a kinase with
specificity for the receptor-activated transcription factors Smad2 and Smad3. Upon
phosphorylation, Smad2 and Smad3 form a Smad complex via association with Smad4,
and translocate to the nucleus to bind DNA and modulate transcription. Additionally,
TGF-β exhibits Smad-independent signaling character, including the activation of Akt55.
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In T cells, TGF-β is a differentiation factor for both Th17 and Treg cells, depending on its
integration with other cytokine signals. TGF-β activation with concomitant IL-6
stimulation results in Th17 differentiation, while TGF-β plus IL-2 induces Treg
development56. For Tregs specifically, Smad3 binds with the TCR-inducible transcription
factor nuclear factor of activated T cells (NFAT) to the CNS1 region of Foxp3 to induce
its expression10,57, and TGFB-/- mice succumb to multi-organ autoimmunity58. By
secretion of TGF-β themselves, iTregs are able to engage in infectious tolerance.
IL-2 is a cytokine that is a T cell growth and differentiation factor, but can also
induce activation-induced cell death59. The IL-2R exists as a heterodimer of one molecule
of its β chain (CD122) in complex with one common γ chain (CD132) and is able to
signal in response to high levels of IL-2. Upon expression of the α chain (CD25) in
activated T cells and Tregs and subsequent binding of αβ to IL-2, a new high-affinity
heterotrimer forms. Janus activated kinase 3 (JAK3) associated with the common γ chain
and JAK1 bound to CD122 phosphorylate the β and γ chains of the IL-2R and each other
to allow assembly of a complex that results in activation of STAT5. Among other roles,
STAT5 binding to the CNS2 region of Foxp3 drives Treg development in concert with
TGF-β60. The role of IL-2 in tolerance is such that IL2-/- and STAT5-/- mice develop fatal
autoimmunity with IBD-like symptoms marked by a massive increase in the infiltration
of activated, proliferating T cells61,62, which can be ameliorated by Treg transfer63,64.
1.5

Summary
In this dissertation, we describe our work profiling the ability of T cells to sense

and respond to extracellular signals during T cell fate decision making en route to iTreg
differentiation with both mouse and human systems. This multi-species approach will
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elucidate mechanisms of iTreg differentiation and function to improve our ability to
design therapeutics for IBDs and other immunopathologies. In chapter 3, we describe for
the first time the human T cell endogenous retinol metabolism pathway via the induction
of RDH10 downstream of PPARγ, and its pro-iTreg character. Chapter 4 contains the
first phenotypic description of T cells from PINK1 knockout mice, where FoxP3
expression is uncoupled from suppressor function. Ultimately, both of these approaches
converge on the PI3K/Akt/mTOR pathway and cellular metabolism, which we posit is
the crux of T cell fate determinism and allows T cells to be masters of signal integration.
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Figure 1.1 T cell fate decisions. Naïve CD4+ T cells integrate signals from their
extracellular environment to determine their effector profile. Stimulation in the presence
of IL-12 induces master transcriptional regulator T-bet, which controls the Th1 response
of IFN-γ, IL-2 and TNF-α to defeat intracellular pathogens and viruses. IL-4 encountered
during activation causes a Th2 program: GATA-3 prompts the secretion of IL-4, IL-5 and
IL-13 to combat extracellular pathogens. RORγT directs the Th17 response after TGF-β
+ IL-6 exposure towards the secretion of IL-17, IL-21 and IL-22 aimed at clearance of
extracellular bacteria. Alternatively, a suppressor response can be initiated by TGF-β and
IL-2 through FoxP3. These designations describe T cell responses in response to
pathogens in general; individual T cells can exhibit mixed character between T helper
subsets and have the ability to switch from pro- to anti-inflammatory. For a more
complete review of CD4+ T cell subset differentiation and function, including that of
follicular helper T cells, Th9 cells, etc., readers are referred elsewhere65.
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Figure 1.2 Mechanisms of iTreg immunosuppression. iTregs have multiple means of cell
contact dependent and independent means of anti-inflammatory activity. Notably, many
contemporary studies examine the activity of iTregs solely via their ability to suppress
bystander T cell proliferation. Figure reproduced with permission from (66).
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Figure 1.3 TCR, CD28 and IL-2 receptors activate the PI3K/Akt/mTOR axis. Upon T
cell activation, PI3K creates a docking site for Akt at the cell membrane where it can be
phosphorylated by PDK1 and mTORC2. Activated Akt binds many downstream proteins
including mTORC1. Coincidentally, Akt was first cloned at the Fox Chase Cancer
Center, 1.7 miles from the suburban Philadelphia house where the author lived as a 5 year
old at the time67. Figure modified from (68), reproduced here under the terms of the
Creative Commons Attribution License.

Copyright © Gavin Isaac Ellis 2013
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Chapter 2: Materials and Methods
2.1 Generation of Induced Regulatory T Cells from Primary Human Naïve and
Memory T Cells
In response to the need for a more thorough understanding of the molecular
events involved in human iTreg cell fate decision making, our lab developed a method to
generate iTregs (CD25hi CD45RA-) from human peripheral blood donors. Notably, we
designed this technique to utilize sub-optimal conditions, so effector T cells (CD25mid
CD45RA-) are simultaneously generated, and memory (CD25- CD45RA+) and naïve
(CD25- CD45RA-) T cells persist, allowing genetic comparisons to be made between
subsets within an individual donor. Figure 2.1 shows a graphical schematic of this
process.
2.1.1

Isolation CD4+ CD25- T cells from human blood donors

Human donations of packed granulocytes were first diluted with phosphate
buffered saline (PBS) at a ratio of 1:5, before overlaying on Lymphoprep separation
medium (Axis-Shield) in 50 mL conical tubes. Tubes spun for 30 minutes at 500 x g with
no brake at room temperature, leaving a sharp, buff colored layer of peripheral blood
mononuclear cells (PBMCs) to transfer by pipette into a fresh tube. PBMCs were
washed, and then subject to EasySep magnetic negative selection (Stem Cell
Technologies) as per manufacturer’s instructions. The EasySep CD4+ T cell kit excludes
cells expressing CD8, CD14, CD16, CD19, CD20, CD36, CD56, CD66b, CD123 or
TCRγ/δ via Tetrameric Antibody Complexes. CD4+ CD25- T cell purity following
execution of kit is routinely >95% and results in cells unattached to any antibodies which
could interfere with downstream applications.

19

2.1.2

Generation of iTregs and Th17 cells from CD4+ CD25- precursors

CD4+ CD25- precursors fresh out of magnetic selection were resuspended in
“iTreg medium” at a concentration of 2 x 106 cells / mL: RPMI-1640 pre-supplemented
with Glutamax-I (2.06 mM, Gibco) and HEPES buffer (25 mM, Gibco) plus fetal bovine
serum (10%, Gibco), penicillin (100 U/mL, Gibco), streptomycin (100 μg/mL, Gibco), βmercaptoethanol (50 μM, Sigma-Aldrich), IL-2 (5 ng/mL, eBioscience) and TGF-β (2
ng/mL, eBioscience). Cell suspensions were plated in α-CD3 coated plates (1 μg / mL,
Clone: OKT3, Bio X Cell) for 6 days, with half of the medium being replaced on day 3.
This cell culture system allows for some versatility, as agonists and antagonists were
added to the cell culture medium where indicated to probe the activation or inhibition of
pathways of interest, and the input population of cells was altered to examine iTreg
differentiation of pure memory or naïve T cells. To adapt this protocol for mouse cells,
IL-2 was used in iTreg medium at 1 ng/mL, and mouse α-CD3 (Clone: 45-2C11, Bio X
Cell) was used. Where noted, all-trans retinol (1 μM), all-trans retinal (1 μM), all-trans
retinoic acid (1 μM), 9-cis retinoic acid (1 μM), RO 41-5253 (1 μM) or citral (5 μM)
were included in the culture medium to influence the retinoic acid pathway, and GW9662
(1 μM) was included to block PPARγ. A representative flow cytometry dot plot can be
found in Figure 2.2 showing the induction of CD25, CD45RA, CTLA-4 and FoxP3 over
the course of 6 days. To generate Th17 cells, enriched CD4+ T cells were cultured in αCD3 coated wells (1 μg/mL) in a medium containing TGF-β (5 ng/mL) and IL-6
(eBioscience, 10 ng/mL) for 3 days, before switching to an IL-23 containing medium
(eBioscience, 10 ng/mL) for another 3 days.
2.1.3

T cell suppressor assay
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As stated previously, no individual protein marker or panel of markers can
definitively define a human Treg cell, and detection of FoxP3 requires permeabilization
of cells, rendering them as non-viable. Therefore, we identified a CD4+ CD25hi
CD45RAlo CD127- cell surface phenotype as our iTreg subset and used a suppressor
assay to show that these are bona fide iTregs. First, iTregs (CD25hi CD45RA-), memory
(CD25- CD45RA-), effector (CD25mid CD45RA-) and naïve (CD25- CD45RA+) T cells
were sorted with a MoFlo cell sorter (Beckman Coulter). During the sorting process,
CD4+ T cells from a heterologous donor were isolated as in section 2.1.1 and then labeled
with 5 mM carboxyfluorescein succinimidyl ester (CFSE, Invitrogen) for 3 minutes at
37°C. Next, cells were resuspended in suppression assay medium: AIM-V supplemented
with penicillin (100 U/mL), streptomycin (100 μg/mL), β-mercaptoethanol (50 μM), IL-2
(5 ng/mL) and TGF-β (2 ng/mL) at various ratios of sorted cells to labeled cells, but so
the total amount of cells per 96 round bottom well was 2 x 105. Treg inspector
suppression beads (Miltenyi Biotec) were added to the suspension at a number equal to
the number of the total cells to drive proliferation by crosslinking of CD2, CD3 and
CD28. After 5 days of co-culture at 37°C, CFSE levels were evaluated by flow
cytometer. Figure 2.3 demonstrates that iTregs were the only subset of T cells that could
suppress the proliferation, and thus the CFSE dilution of labeled cells. To adapt this
procedure for use with mouse cells, Mouse T-Activator CD3/CD28 Dynabeads (Gibco)
were used as a stimulus instead of iTreg inspector beads and IL-2 was used in the
suppression assay medium at 1 ng/mL.
2.2

Flow cytometry
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3x105 cells were resuspended in 100 μL flow cytometry buffer (PBS, 0.5% bovine
serum albumin, 2 mM EDTA) and stained with the following extracellular antibodies at
manufacturer’s recommended concentrations (eBioscience): CD4, CD25, CD44, CD62L
and CD45RA. For detection of intracellular proteins, cells were fixed and permeabilized
as per manufacturer’s instructions with the FoxP3 / Transcription Factor Staining Buffer
Set (eBioscience) with 2% normal rat serum to block non-specific staining, before
staining with antibodies directed against CTLA-4, RORγT or FoxP3. Since GLUT1 and
p-Akt-473 antibodies (Santa Cruz Biotechnology Inc.) were not fluorochrome
conjugated, incubation with labeled secondary anti-IgG antibody (Invitrogen) facilitated
their detection. For intracellular cytokine detection, T cells were cultured simultaneously
with PMA (50 ng/mL), ionomycin (500 ng/mL) and GolgiStop (BD Biosciences, 4 μL/6
mL medium) for 5 hours at 37°C before staining with the BD Cytofix/Cytoperm
Fixation/Permeabilization kit and antibodies detecting IL-2 or IL-17 (eBioscience). Flow
cytometry without sorting was performed on an LSRII cytometer (BD Biosciences) and
analyzed with FlowJo software (Tree Star Inc.). Cell sorting was performed as
extracellular staining above with the additional steps of DNaseII addition (1 μg/mL) and
a pass through a 70 μm filter to prevent clogging of the FACSAria cell sorter (BD
Biosciences). To evaluate Δψm, cells were incubated with 30 nM tetramethylrhodamine
ethyl ester (TMRE, Invitrogen) for 30 minutes in RPMI at 37°C before immediate
analysis.
2.3

Microarray
Total RNA was extracted from 5-7 x 106 FACS sorted CD4+ human T cells

(CD25-, CD25low or CD25hi iTregs) with TRIzol (Life Technologies), from which cDNA
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was immediately generated with SuperScript III First-Strand Synthesis Kit as per
manufacturer’s instructions (Invitrogen). With assistance from the University of
Kentucky Microarray Facility, we quantified cDNA with the Affymetrix GeneChip
System (Human Genome U133 Plus 2.0 Array microchip) compared to GAPDH as a
reference control in triplicate. Results are shown normalized to values for CD25- subset.
2.4

Western Blot
To perform Western blotting, cells were first lysed with cold

radioimmunoprecipitation assay (RIPA) buffer: 50 mM Tris-HCl, pH 7.4, 150 mM NaCl,
0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 1 mM phenylmethylsulfonyl
fluoride and 1X Halt Protease Inhibitor Cocktail (Thermo Scientific). Next, protein
lysates were mixed with 2X Laemmli buffer and boiled for 10 minutes at 90°C before
being loaded in wells of a 10% or 12% SDS-PAGE gel. Gels were then run at a voltage
of 100 V for 1-2 hours to separate proteins by size. Proteins were transferred to a
polyvinylidene fluoride (PVDF) membrane which was then blocked for 1 hour at 37°C in
2% fetal bovine serum in TTBS buffer (50 mM Tris, 150 mM NaCl, 0.05% Tween-20).
Membranes were incubated overnight at 4°C in primary antibody solution diluted as per
manufacturer’s instructions, washed and, when applicable, incubated at room temperature
for 30 minutes in antibody solution containing secondary α-IgG antibody conjugated to
horseradish peroxidase. Proteins were detected via chemiluminescence (Pierce ECL
Western Blotting Substrate, Thermo Scientific) and autoradiography film. When needed,
blots were stripped of antibody with stripping solution (2% sodium dodecyl sulfate, 62.5
mM Tris HCl pH 6.8 and 100mM β-mercaptoethanol) and 30 minutes of incubation at
55°C before re-probing as above.
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2.5

qPCR
5x106 magnetically sorted CD4+ T cells were cultured for 24 hours in iTreg

medium containing either DMSO, RSG (1 μg) with 9-cis RA (1 μg) or GW9662 (1 μg)
and 9-cis RA (1 μg) on α-CD3 coated plates to stimulate or block PPARγ, respectively.
RNA was isolated from cells with the Quick-RNA MiniPrep kit (Zymo Research) per
manufacturer’s instructions, followed by cDNA creation from 0.5 μg RNA with
SuperScript III First Strand Synthesis System (Invitrogen). 4 μL of cDNA was run in a 10
μL reaction with 5 μL PerfeCTa qPCR FastMix (Quanta Biosciences) and 0.5 μL of a
20x pre-made primer:probe Taqman gene expression assay (Applied Biosystems). The
following primers:probe mixes were used: GAPDH: Hs99999905_m1 and RDH10:
Hs00416907_m1. Reaction was run on the “Quick Start” setting of a StepOnePlus RTPCR system (Life Technologies). Data were analyzed by the ΔΔCT method.
2.6

Immunoprecipitation
PPARγ (Cell Signaling, Clone 81B8) or IgG control antibodies were conjugated

to A/G PLUS agarose beads (Santa Cruz) for 30 minutes at room temperature before
washing three times. Lysates were then added to beads and incubated overnight at 4°C.
2.7

Electrophoretic mobility shift assay (EMSA)
Day 6 T cell lysates were obtained by lysing cells in RIPA buffer. Detergents

were removed from lysates by dialyzing proteins into dialysis buffer (10% glycerol, 1
mM EDTA, 100 μM PMSF, 50 mM Tris pH 7.5, 0.01% Tween-20, 50 mM KCl, 1 mM
DTT) with a Slide-A-Lyzer 3.5K dialysis cassette (Thermo Scientific). Each 1 μL of the
resulting lysate contained protein from ~12,000 cells. The following single stranded
DNA probes were created by self-ligation with their exact complements by heating up

24

equal volumes of 10 mM oligonucleotide solutions in boiled water for 10 seconds and
letting cool to room temperature (PPRE in bold): Wild type RDH10 5’CTGTTTCTCCTAAATAGGTCACATTAAACCTCATTA-3’, Mutant RDH10 5’CTGTTTCTCCTAAATTCCGACCATTAAACCTCATTA-3’. Hot probes were ordered
pre-biotinylated on their 5’ ends. Whole cell lysate and probe were mixed in EMSA
binding buffer (10 mM HEPES pH 7.9, 1 mM EDTA, 60 mM KCl, 7% glycerol) with
poly-dI:dC and incubated at room temperature for 45 minutes before electrophoretic
resolution on a 6% non-denaturing polyacrylamide gel. Each EMSA reaction contained
14.5 μL binding buffer (containing poly-dI:dC), 1.5 μL probe, variable amounts of lysate
and dH2O to bring the total reaction volume up to 20 μL. DNA/protein complexes were
then transferred to a Biodyne nylon membrane, UV crosslinked for 30 seconds and
blocked overnight. Detection of complexes was performed with Chemiluminescent
Nucleic Acid Detection Module Kit (Thermo Scientific). Where indicated, lysates were
immunoprecipitated with either rabbit α-PPARγ (Cell Signaling, Clone: 81B1) or Ig
control antibodies overnight at 4°C as described above.
2.8

Mice
6-8 week old PINK1 knockout mice were generated on a 129/Sv background69

before crossing with C57BL/6 for at least 10 generations. All mouse work was approved
by the Institutional Animal Care and Use Committee at the University of Kentucky.
2.9

in vitro T cell activation
1 μg of α-CD3 antibody (Clone: 45-2C11) with or without 500 ng of α-CD28

(clone: 37.51, eBioscience) antibody was added to a single cell suspension of 106 LN
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CD4+ T cells and incubated for 15 minutes on ice. Bound antibody was then cross-linked
with 2 μg of α-IgG for 3 minutes at 37°C and quenched with cold RPMI.
2.10

Extracellular flux analysis
Extracellular flux analysis was performed on an XF-96 bioanalyzer (Seahorse

Bioscience) according to manufacturer’s protocol. First, XF assay medium was pH
balanced and supplemented with both 25 mM glucose and 1 mM sodium pyruvate. 4x105
T cells per well were resuspended in XF assay medium and attached to a 96-well plate
pre-coated with Cell-Tak (BD Biosciences) for 20 minutes at a concentration of 22.4
μg/mL, followed by gentle centrifugation. During each run, the bioanalyzer injected
solutions from each of four separate ports (A-D) into the each well. Because of the
additional volume from each injection, oligomycin in port A was formulated at 8X final
concentration, (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone) FCCP in port B
at 9X, etomoxir in port C at 10X and rotenone / antimycin A in port D at 11X.
Oligomycin was used at a final concentration of 1 μM, FCCP was used at 1.5 μM,
etomoxir at 200 μM and rotenone / antimycin A were injected at the same time, each at 1
μM. Samples were either run in triplicate or quadruplicate, and the changes in oxygen
consumption rate (OCR) and extracellular acidification rate (ECAR) were measured and
compared to background correction wells containing no cells, but still receiving each
liquid injection. The bioanalyzer was programmed to make 3 measurements before port
A’s injection (baseline), 3 measurements after injection of oligomycin, FCCP and
rotenone / antimycin A and 5 measurements after etomoxir. Derived perimeters were
calculated as follows, with letters corresponding to Figure 4.5A/B: Basal resp. = A-E,
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ATP Prod. = A-B, max resp. = C-E, spare respiratory capacity (SRC) = C-A, fatty acid
(FA) resp. = C-D, Non-FA resp. = D-E.
2.11

Statistical analysis
Statistical comparisons were made using unpaired, 2-tailed Student’s t-test. A p

value of < 0.05 was used as the cutoff for statistical significance.
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Figure 2.1 Generation of iTregs from human peripheral blood donors. Following
isolation of PBMCs from granulocyte samples via gradient centrifugation, magnetic
negative separation isolated CD4+ T cells, which were cultured on α-CD3 coated plates in
medium containing TGF-β and IL-2. On day 6 of culture, fluorescence activated cell
sorting (FACS) separated iTregs (CD25hi CD45RA-) from effector (CD25mid CD45RA-),
memory (CD25- CD45RA-) and naïve (CD25- CD45RA+) T cells. To test suppressor
function, each subset was co-cultured with CFSE labeled, autologous T cells and αCD3/α-CD28 beads, before flow cytometric analysis of CFSE dilution.
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Figure 2.2 Representative plot of iTreg differentiation from CD25- human donor cells.
Flow cytometric pseudocolor dot plots demonstrate the kinetics of iTreg development as
generated in Figure 2.1. iTreg yield fluctuated from 5%-40% depending on donor
variability and inclusion of ligands in the culture medium.
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Figure 2.3 The iTreg subset (CD25hi CD45RA-) has demonstrable suppressor activity.
Cultured CD4+ T cells were sorted into naïve (CD25- CD45RA+), memory (CD25CD45RA-) or iTreg (CD25hi CD45RA-) subsets and incubated with CFSE labeled,
autologous CD4+ T cells for 5 days. Each CFSE peak represents one cell division.
Histograms above are representative of 3 human experiments performed at a ratio of 3
CFSE labeled T cells to 1 iTreg, and represent the general trend expected to occur in
healthy humans and wild type mice when probing the suppressor activity of functional
iTregs.
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Chapter 3: Human iTreg development is enhanced by the T cell autonomous alltrans retinoic acid synthesis pathway mediated by PPARγ
3.1

Introduction
Aside from the TCR, co-stimulatory and cytokine signals received during

priming, a T cell must integrate signals from other molecules that may be in the vicinity
to further refine the T cell response. Nuclear receptors, including peroxisome
proliferator-activated receptor-γ (PPARγ) and retinoic acid receptor-α (RARα), are a
family of ligand inducible transcription factors that can execute that need by responding
to signals from fatty acids, eicosinoids, prostaglandins and dietary ligands (PPARγ) or
retinoids (RARα).
The effects of PPARγ on downstream transcription are enacted by several distinct
mechanisms70. Generally, it traffics to the nucleus where it constitutively binds a PPARγ
response element (PPRE) half site via its zinc finger DNA binding domain and
heterodimerizes with the retinoid X receptor (RXR). In this basal, non-ligand bound state,
PPARγ’s transactivation domain recruits a complex of transcriptional co-repressors to
downregulate the expression of responsive genes. Agonist binding induces a
conformational change that stabilizes the molecule’s AF2 domain, and encourages a
switch of the co-repressors for co-activators, many of which are then sequestered from
the pro-inflammatory NF-κB. Alternatively, PPARγ can negatively regulate other
transcription factors through transrepression by mechanisms that are still becoming clear.
In macrophages, LPS induces transcriptional activation of iNOS by a similar exchange of
co-repressors for co-activators. In the presence of ligand however, PPARγ is
SUMOylated and trafficked to the iNOS promoter where it prevents dissociation of co-
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repressors71. In the gut, the commensal species Bacteroides thetaiotamicron attenuates
inflammation by directing PPARγ to shepherd the RelA subunit of NF-κB out of the
nucleus and into the cytoplasm72. The multiple mechanisms of action, diversity of targets
and non-specific effects of its ligands have made PPARγ a relatively difficult molecule to
study.
Though several endogenous ligands have been proposed for PPARγ including
eicosanoid 15-deoxy-Δ12,14 prostaglandin J2 (15d-PGJ2), poly-unsaturated fatty acids and
oxidized low-density lipoproteins73, these molecules were not found in high enough
concentrations in vivo to be considered physiologically relevant modulators. Still, PPARγ
has been an active target of pharmaceutical intervention with synthetic ligands. Members
of the thiazolidinedione (TZD) class of drugs including pioglitazone, ciglitazone,
rosiglitazone (RSG) and troglitazone have been used to treat type 2 diabetes74 due to
PPARγ’s ability to decrease insulin resistance, but are associated with congestive heart
failure75 among other side effects, which have caused their removal from the market.
Transcriptional roles for PPARγ have been noted in the control of inflammation,
metabolism, and adipogenesis76. PPARγ stimulation by TZDs induces the differentiation
of pre-adipose cells77, positioning PPARγ as the master regulator of adipogenesis. In
dendritic cells and macrophages, PPARγ activation induces an anti-inflammatory
phenotype by influencing a range of characteristics71,78,79. For one such change in human
dendritic cells, treatment with RSG increased the expression of several molecules
involved in the metabolism of vitamin A (retinol) into its transcriptionally active form,
all-trans retinoic acid (ATRA). Vitamin A has a long established role in the proper
function and development of the immune response80. As part of the gut immune system,
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CD103+ dendritic cells35, intestinal epithelial cells81, mesenteric lymph node stromal
cells82 and CD14+ macrophages83 possess the machinery to metabolize and secrete
ATRA, in addition to other extra-mucosal tissues such as testicular Sertoli cells84. The
presence of ATRA during naïve T cell priming synergizes with TGF-β to increase the
development, stability and relative suppressor strength of iTregs35,85–87. ATRA also
actively represses the expression of RORγT, the master transcription factor of the Th17
lineage88 and induces gut homing molecule expression86. When provided ATRA by
CD103+ dendritic cells or from other sources, lymphocytes upregulate expression of the
chemokine receptor CCR9, which causes trafficking to the CCL25 producing areas of the
small intestinal crypt regions, and the integrin α4β7, which binds to MAdCAM-1
expressed on blood vessel endothelial cells of the intestinal, respiratory and urogenital
tracts89.
Retinol is converted to ATRA via a 2 step process: retinol is reversibly oxidized
into retinal by a member of the short-chain dehydrogenase/reductase (SDR) or alcohol
dehydrogenase (ADH) families as the rate limiting step, and retinal irreversibly becomes
ATRA via a secondary oxidation by a retinaldehyde dehydrogenase (RALDH). ATRA
binds to RARs, which form obligate heterodimers with RXRs at retinoic acid response
elements (RAREs) to modulate transcription. RDHs are largely thought to have
redundant function because of their wide range of expression patterns and overlapping
function90, so much of the focus on pathway regulation has been on the more tissuespecific expression of RALDHs. However, recent work has shown that retinol
dehydrogenase 10 (RDH10), an SDR, is non-redundantly required for embryonic
development and post-natal viability and spermatogenesis84, despite the expression of
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other ADHs91. The sub-cellular localization of RDH10 to lipid bilayers gives it exclusive
access to a pool of retinol contained within retinol binding protein-free membranous
vesicles92.
Since PPARγ activation trends towards an anti-inflammatory response and its
expression is necessary for murine iTreg development93, we reasoned that human iTregs
might be similarly regulated, giving them the ability to respond to similar external
signals. In this chapter, we confirm that T cell expressed PPARγ is important for human
iTreg development, and that its ligand-induced activation endows iTregs the ability to
autonomously metabolize retinol into endogenous ATRA via the direct binding of
PPARγ to the RDH10 locus.
3.2

Results
3.2.1

PPARγ is necessary for optimal human Treg development

To determine which transcription factors could play a role in the development,
stability and/or function of iTregs, we performed a microarray analysis comparing gene
expression levels from iTregs, memory, naïve and effector T cells within individual
human donors. Upon examining the list of transcription factors with a greater than two
fold enrichment in iTregs versus CD25- T cells (Figure 3.1A), we noticed an upregulation
of Pparg (Figure 3.1B), which we confirmed at the protein level (Figure 3.1C). Since
PPARγ has genomic and non-genomic function, we also demonstrated that the PPARγ
expressed in iTregs and naïve T cells has the ability to bind a consensus PPRE (Figure
3.1D). As a conditional PPARγ knockout in murine CD4+ T cells was correlated with
fewer Tregs in mice94, we examined the role of this nuclear receptor in human iTreg
generation. Though addition of the PPARγ agonist RSG to culture medium had no
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enhancing effect on iTreg differentiation, pharmacologic inhibition with GW9662
subdued iTreg development (Figure 3.1E/F).
3.2.2

Retinol enhances iTreg generation in human CD4+ CD25- T cells

downstream of PPARγ
A further investigation of our microarray analysis revealed an enrichment in the
levels of RDH10 within the iTreg subset and a corresponding decrease in DHRS3 (the
SDR1 gene), an antagonistic enzyme which preferentially catalyzes the reduction of
retinal back to retinol95. In addition, the cytochrome P450 family member CYP3A5,
which degrades ATRA into 4-hydroxy-retinoic acid96 was reduced, and expression of
RARA was increased (Figure 3.2A). The summation of these genetic changes creates an
overall intracellular environment favoring the synthesis, stability and signaling ability of
ATRA. As multiple immune and structural cell types in the gut produce ATRA, we asked
whether this machinery would endow iTregs with the ability to perform this function
intrinsically. The inclusion of either retinol or retinal into the cell culture medium
increased iTreg development with potency equal to that of ATRA at equimolar
concentrations (Figure 3.2B). Similar studies performed with ATRA in mouse and human
systems suggest that ATRA responsiveness is restricted to naïve T cells85,97, which holds
true in our iTreg differentiation platform, where we used magnetic negative separation to
isolate T cells enriched for either memory or naïve T cells (Figure 3.2C). The stimulatory
effect of retinol on naïve T cells could be abrogated by simultaneous addition of the
RALDH antagonist citral or RARα antagonist RO 41-5253, demonstrating the
importance of RARα signaling over RAR-independent effects (Figure 3.2D/F). The iTreg
stimulating properties of retinol agonism were not affected by GW9662, situating the
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RARα pathway downstream of PPARγ (Figure 3.2E/F). These results suggest a
functional T cell intrinsic ATRA synthesis pathway in naïve T cells downstream of
PPARγ and mediated by changes in gene expression of the RARα pathway.
Because RSG treatment induced RDH10 expression and ATRA secretion in
human dendritic cells and ATRA rescues iTreg differentiation after PPARγ blockade, we
cultured sorted, CD4+ T cells in iTreg medium containing either RSG and 9-cis RA to
stimulate PPARγ, GW9662 and 9-cis RA to inhibit PPARγ or vehicle control. After 24
hours of stimulation, PPARγ stimulated T cells exhibited a 6-fold increase in RDH10
transcript levels compared to vehicle control, indicating the conservation of a PPARγ to
RDH10 pathway similar to that in other cell types (Figure 3.2G).
3.2.3

PPARγ increases transcription of RDH10 via direct binding

The pleiotropic nature of PPARγ leaves doubts as to whether its effect on iTreg
development and RDH10 induction is direct or indirect. Upon examination of the RDH10
gene, we found an evolutionarily conserved PPRE half site slightly downstream of exon
2, which we thought might allow PPARγ binding (Figure 3.3A). T cell lysates were able
to bind to a biotinylated double stranded DNA oligonucleotide probe representing the
putative PPRE and its surrounding nucleotides in an EMSA. A wild type cold competitor,
but not one in which the PPRE had been altered, was able to compete away binding of the
biotinylated form, demonstrating the necessity of the PPRE for binding (Figure 3.3B).
Since we used a whole T cell lysate, our experiment said nothing about the identity of the
protein bound to the probe. Immunoprecipitation of the lysate with an α-PPARγ antibody
eliminated one of the bands, identifying a PPARγ-containing complex as directly binding
to this site (Figure 3.3C).
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3.3

Discussion
In this chapter, we establish the importance of PPARγ to human iTreg

development, and demonstrate that the PPARγ/RDH10 transcriptional pathway seen in
dendritic cells works similarly in T cells, imparting the ability to synthesize ATRA
autonomously. As ATRA is only found at very low levels in serum, only un-metabolized
forms are available for cellular uptake. In order to signal through the RAR/RXR
heterodimer, a cell must first oxidize retinol to ATRA or have it provided by a cell type
which can catalyze this conversion. When an iTreg strays from ATRA-producing
CD103+ dendritic cells and moves to sites other than organized lymphoid organs, its
expression of RDH10 endows it the ability to metabolize its own ATRA. Since we have
not demonstrated that iTreg-produced ATRA has the ability to leave the cell, this activity
may serve as a mechanism whereby iTregs stabilize their own identity. If iTregs have the
ability to provide ATRA to other cell types as DCs do, close proximity of cells is most
likely required. T cells have the ability to interact with lymphoid cells such as non-ATRA
producing APCs, B cells, and other regulatory and non-regulatory T cells in addition to
non-lymphoid cells. Following, iTreg-produced ATRA could support intestinal
homeostasis by inducing the proliferation, mucosal homing and IgA class switching of
Peyer’s patch and peripheral B cells89 or supporting the maintenance of the intestinal
epithelial barrier where PPARγ expression is high98.
In terms of T cell immunity, ATRA producing T cells more than likely play
important roles in gut immunity and oral tolerance. iTregs secreting both TGF-β and
ATRA engaging in homotypic interactions with resting T cells99 could impart infectious
tolerance upon the latter. Mucosal iTregs which recognize food peptide could induce
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tolerance for the same antigens when found in the periphery, suppressing proinflammatory responses and inducing iTreg differentiation of other T cells. In a PPARγ
deficient mouse model of colitis, both vitamin A deficient and vitamin A high diets were
more protective compared to a diet at the normal dietary range100. Anti-colitic Tregs in
the former model were CD103+ CCR7+ and correlated with increased thymic Treg output,
while those in the latter expressed CCR9 and α4β7 and trafficked better to the small
intestine. Therefore, the tight control of retinoic acid is essential for proper gut immunity.
In addition to its effect in a metabolized state, retinol has other ATRA-independent
effects on gene expression. In studies where mice are put on retinol-free diets,
supplementation with ATRA rescues some, but not all effects including
spermatogenesis101, and retinol is required for B cell growth102. Vitamin A can also tilt
the balance of the Th1/Th2 axis by downregulating Th1 responses and supporting Th2
immunity, which has been suggested to be a key component in the prophylactic effect of
helminthic therapy for IBD103.
Though the role of retinoids in the Treg response has been widely demonstrated, a
complementary hypothesis posits that ATRA could be a general proliferation and
differentiation factor, based on work detailing its role in promoting pro-inflammatory
responses against Toxoplasma gondii104. In addition, low doses of ATRA have shown
properties of adjuvanticity: IL-15 primed tolerogenic DCs to produce IL-12 and IL-23
which synergize with ATRA to block iTreg formation and promote the Th1 and Th17
subsets105. Therefore, it seems as if the context in which ATRA is presented to T cells
will determine the direction of ATRA’s differentiation-inducing effect, where one would
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expect the recognition of pathogen associated molecular patterns to influence the
direction of the response to oral antigen.
Despite the importance of RDH10 to pre-natal development and post-natal
viability, viable RDH10-/- mice have been generated by rescuing the phenotype with
maternal dietary supplementation of all-trans retinal106. These mice exhibit truncated
forelimbs and a characteristic “spinning” phenotype, consistent with the role of RDH10
in hindbrain development107. In the absence of any immunological challenge, these mice
have not been reported to have any immunological defects including colitis. However, a
preliminary experiment of ours did demonstrate a consistent accumulation of CD19+ B
cells in peripheral lymph nodes isolated from heterozygous mice expressing only one
functional RDH10 allele (data not shown), potentially due to reduced mucosal trafficking.
We believe that further delving into the immunological phenotype of full RDH10
knockout mice in situations of active inflammation will reveal a unique role for RDH10
in immunosuppression. Though the ability to synthesize retinoic acid from retinol is
shown here to be a novel pathway for T cells, quite a bit of redundancy exists within
hematopoietic and non-hematopoietic cell types, especially in the gut. More often than
not, duplications in systems provide a failsafe mechanism to guard against dysfunction,
which we believe is the case here, as loss of intestinal homeostasis invariably causes
inflammation, discomfort and reduced nutrient absorption needed to sustain life.
However, autonomously produced endogenous ATRA likely has a few functions unique
to T cells. To tease apart the in vivo function of this pathway in T cells, we have recently
generated a mouse which lacks RDH10 expression in all CD4+ and CD8+ T cells (CD4Cre, RDH10Fl/Fl) mice. Experiments involving mouse models of infection, oral tolerance
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and colitis are ongoing. Although non-functional PPARγ is only associated with
metabolic disorders and diabetes in humans, CD14+ intestinal macrophages in healthy
controls express significantly higher levels of RDH10 than those isolated from Crohn’s
disease patients83. This result highlights RDH10’s role in intestinal homeostasis, as its
absence in certain cell types is associated with disease.
The identification of which specific PPARγ-induced effects are anti-colitic and
which cell types are its effectors should increase therapeutic efficacy and decrease side
effects. Here, we identify T cells as one such cell type, and their differentiation into
iTregs as the PPARγ-regulated process which could be targeted by iTreg therapy. Several
reports have proposed PPARγ as a therapeutic target in IBD108–110, as mice harboring
PPARγ-deficient enterocytes and hematopoietic cells have exasperated colitis in the
TNBS and T cell transfer models93. In human IBD, a susceptibility locus has been
preliminarily detected on chromosome 3p26, close to the PPARγ gene located at 3p253p26111, and a PPARγ polymorphism has been found to be underrepresented in a
population with Crohn’s disease112. Additionally, an rRNA analysis of the gut
microbiome identified an underrepresentation of bacteria that produce the fatty acid
PPARγ ligand butyrate in IBD microbiomes113. These and other factors result in a marked
decrease in PPARγ protein and mRNA levels from colonic biopsies in both Crohn’s
disease and ulcerative colitis patients that do not extend to levels in peripheral blood114.
Though PPARγ ligands reduce inflammatory cytokine secretion and ameliorate DSS
colitis110 in mouse models, the expression pattern and pleiotropy of PPARγ reduces the
ability to target certain cells, and concerns over an increased risk of morbidity and
mortality have seen TZDs off the market.
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To activate a single, relevant arm of the PPARγ signaling pathway to reduce off
target effects, we envision retinoid therapy as a therapeutic modality to treat
autoimmunity, and particularity IBD. Mice on vitamin A high diets (25,000 IU/kg, 10X
of normal diet) had more CCR9+ gut Tregs in intestinal sites (jejunum, ileum, colon) and
a less severe phenotype of spontaneous colitis100. Oral ATRA has been used successfully
to combat acute promyelocytic leukemia (APML), a blood cancer caused by a
translocation of the RARA gene. However, 26% of those prescribed ATRA develop
retinoic acid syndrome, a multi-system morbidity characterized by fever, weight gain,
pleural and pericardial effusions, acute renal failure and death in some cases115. Oral
retinol therapy could hold greater therapeutic benefit based on its inclusion in a normal
diet and the reduction of off target effects mostly limited by the cell-type specific
expression of both an RDH and a RALDH. Efficacy could also be boosted by transducing
T cells ex vivo with an RDH10 lentiviral vector, especially if RDH10 expression is
deficient, as it is in CD14+ lamina propria macrophages isolated from CD patients83, or
with a suicide vector that induces apoptosis if a transferred cell loses FoxP3 expression2.
Stimulation of PPARγ by food antigens116, fatty acid-derived eicosanoids or poly
unsaturated fatty acids might serve to signal to the responding cell of fat soluble vitamins
in the vicinity, and to prepare the machinery to metabolize the vitamin into a
transcriptionally active form. Dietary retinol is ingested from plant sources in a provitamin carotenoid form such as β-carotene, or via animal sources as a retinyl ester.
Hydrolytic enzymes either secreted by the pancreas or located in the small intestinal
microvilli initially free retinol from its lipid carrier, allowing enterocytic uptake. Once
across the epithelial cell barrier, retinol is re-esterified with long chain, unsaturated fats,
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like the PPARγ-activating linoleic acid117,118, and assembled into chylomicrons. Indeed,
increased dietary fat ingestion provides the raw materials for chylomicron formation, and
increases retinol uptake117. Unpacking of chylomicrons is a concerted effort:
glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein
(GPIHBP1) binds the chylomicron, so triglycerides can then be hydrolyzed into fatty
acids by lipoprotein lipase (LPL). Notably, GPHIBP1119 and LPL120 are both PPARγ
responsive proteins. Radiotracing experiments show accumulation of dietary retinol in
the lymph nodes, and since chylomicrons can also stimulate T cell proliferation121 needed
for iTreg development and transport oral antigen from the gut lumen to the MLNs122, this
provides a putative mechanism for oral tolerance.
The subcellular localization of RDH10 provides a clue as to how its function may
be involved in lipid metabolism, PPARγ stimulation and mitochondrial oxidative
phosphorylation (OXPHOS). In transfected COS7 cells, RDH10-GFP can be found
mainly associated with the mitochondrial and mitochondrial-associated membrane
(MAM) fractions. The MAM is a subsection of the ER in close enough proximity to
mitochondria to influence its function and is the site of lipid droplet biogenesis. Upon the
budding off of new lipid droplets, RDH10 leaves the mitochondria and MAM, and
instead can be found in the membrane of the nascent lipid droplets123. In the case of
retinoid sufficiency, retinyl esters are enveloped in the droplets, which can be mobilized
into retinol by membrane associated lecithin retinol acetyltransferase (LRAT)124 and then
oxidized by RDH10 found in the same lipid monolayer when needed.
Overall, the work shown in this chapter supports the following model (Figure
3.4). During TCR stimulation in the presence of IL-2 and TGF-β, T cells accumulate
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unsaturated fatty acids as part of chylomicrons and/or esterified to molecules of retinol.
As ectopic expression of PPARγ increases triglyceride droplet formation from the ER in
fibroblasts125 and Pparg transduction/stimulation of T cells induces several fatty acid
transporter and synthesis genes126, we would expect nascent lipids to form within
PPARγ+ iTregs. During this process, PPARγ upregulates RDH10, which relocates from
the ER to the lipid droplet membranes concurrently with LRAT. As in retinal pigmented
epithelial cells of the eye, these new lipid droplets will contain retinyl esters, and
constitute an intracellular store. Though the role of ATRA in maintaining oral tolerance is
well established, contemporary thought does not comment on the fate of tolerized T cells
in the periphery. Upon egress from the mucosal immune system, an iTreg encountering
its cognate antigen will most likely do so in the context of an ongoing, pro-inflammatory
response. In this case, intracellular ATRA and PPARγ ligands ferried to the site of
infection by RDH10+ iTregs could impart anti-inflammatory effects upon the initiating
innate cells, induce FoxP3 expression in other responding T cell clones which have never
entered the mucosal immune system and reinforce a cell’s own iTreg phenotype. As each
T cell clone in the microenvironment receives slightly different signals depending on the
specific APC it interacts with and its location within the body, retinoic acid secretion
could be a signal from an individual cell as a vote towards a unified immune response,
similar to the “waggle dance” performed by individual honey bees to direct group
decision making in the scouting of potential nest sites127. For these reasons, it has not
escaped our notice that PPARγ might coordinate feeding, vitamin A ingestion and
chylomicron formation as a mechanism to induce oral tolerance, for which α4β7, CCR9
and MLN-to-lamina propria trafficking play a significant role128. Future experiments
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testing the validity of this model will contribute to our knowledge of intestinal iTreg
development and aid in the development of novel therapeutics based on this
understanding.
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Figure 3.1 PPARγ is necessary for optimal human iTreg development. (A) Transcription
factors with >2 log2 fold increased expression in sorted iTregs (CD25hi CD45RA-) versus
CD25- T cells as assessed by microarray. Each of three donor samples was run in
triplicate and compared to the other subset within the same individual. Note the increase
in Foxp3 as an internal control. (B) Pparg gene expression among CD25-, effector
(CD25low) and induced regulatory (CD25hi CD45RA-) T cells, normalized to CD25expression levels from the same experiment as 3.1A. (C) Protein expression of PPARγ
from the cell types sorted as in (B) as visualized by Western blot. (D) Nuclear lysates
from the indicated cell types were added to individual wells containing fixed PPRE
oligonucleotides in an ELISA based assay as measured by 450 nm light absorbance. NSB
= negative control. (E) Representative flow cytometry pseudocolor plot of iTreg
development over the course of 6 days in culture in the presence of DMSO or 1 μM
GW9662. Number in upper left corner of plot represents the percentage of iTregs (grey
box) among all CD4+ cells. (F) Percentage of iTreg development from 6 separate, paired
human donors from three separate experiments, cultured with either GW9662 or vehicle
control (DMSO), * p < 0.05, horizontal black bar represents the average value.
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Figure 3.2 PPARγ controls the endogenous retinoic acid metabolism pathway in human
iTregs through RDH10. (A) Microarray analysis of gene expression levels from CD25-,
CD25low or iTregs (CD25hi CD45RA-) for RDH10, DHRS3 (SDR1), CYP3A5 and RARA
as performed in Figure 3.1. (B) Human CD4+ T cells were cultured in α-CD3 coated
wells for 6 days in iTreg medium containing 1 μM retinol, 1 μM retinal, 1 μM ATRA or
vehicle control (DMSO). Overlaid number represents the percentage of iTregs (grey box)
among all live CD4+ T cells. (C) Naïve and memory CD4+ T cells isolated from the same
donor were cultured in iTreg medium for 6 days with either DMSO or 1 μM ATRA. (D)
Representative flow cytometry pseudocolor plot of naïve CD4+ T cells incubated in iTreg
medium with retinol (top left), retinol + 5 μM citral (top right), DMSO (bottom left) or
retinol + 1 μM RO 41-5253 (bottom right) for 6 days. (E) CD4+ T cells were incubated in
iTreg medium with GW9662 + ATRA for 6 days. (F) Bar graph summarizing all donors
from figures 3.1E, 3.2B and 3.2E, n = 3-7 individual human donors from 5 independent
experiments, * p < 0.05. (G) RDH10 expression normalized to GAPDH as determined by
qRT-PCR after 24 hour incubation with 1μM RSG + 1 μM 9-cis RA or 1 μM GW9662 in
iTreg medium, n = 1 human donor, performed in triplicate, error bars represent the
relative quantification minimum and maximum based on the standard error of calculated
CT values.
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Figure 3.3 PPARγ directly binds to RDH10. (A) Graphical representation of human
RDH10 locus, its exons (black), untranslated regions (white) and its putative PPRE
downstream of exon 2 (yellow) (top). Conservation of human, mouse (top) and cow
(bottom) RDH10 loci as visualized by VISTA Browser. Blue sections correspond to
exons, putative PPRE designated by a vertical yellow bar on the left side of the figure
adjacent to exon 2 (middle). Multiple genome alignment of RDH10 loci showing nucleic
acid level conservation of PPRE site, bases not matching consensus genome sequence are
colored. (B) EMSA of human T cell nuclear lysates incubated with probes as shown
below the gel, n = 1 human donor. (C) EMSA with identical lysates from (B) preimmunoprecipitated with α-PPARγ antibody or IgG control antibody, n = 1 human donor.
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Figure 3.4 Chapter 3 model. Upon TCR stimulation in the presence of IL-2 and TGF-β
(not shown), stimulated T cells begin to sense their environment. Fatty acids from the
vicinity can stimulate PPARγ into upregulating expression of RDH10 via direct binding
downstream of its exon 2. Membrane bound retinol can then be metabolized by RDH10
and RALDH into ATRA to bind to RARα and boost FoxP3, CCR9 and α4β7 expression.
In addition, PPARγ stimulation will induce new lipid droplet formation in vesicles
containing LRAT and RDH10 already present in the ER, giving LRAT the ability to
esterify and store any remaining free retinol into the nascent retinosome to act as an
intercellular store in close proximity to RDH10.

Copyright © Gavin Isaac Ellis 2013
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Chapter 4: Mitochondrial and cytosolic roles of PINK1 shape iTreg development
and function
4.1

Introduction
The activation of a CD4+ T cell is an energetically expensive process which

encompasses both cellular division and the de novo synthesis of proteins and organelles
initially, followed by cell fate decision making and acquisition of an appropriate effector
phenotype. To support the new energetic needs of an activated, differentiating cell, a
rapid re-reorganization of the cell’s metabolic machinery takes place centered on the
control of mitochondrial dynamics.
Cells use adenosine triphosphate (ATP) as a form of “molecular currency” to
transfer the power stored in its two high-energy phosphate bonds to use as co-factors in
enzymatic reactions. In animal cells, ATP is generated from adenosine diphosophate
(ADP) and a free phosphate group via a combination of anaerobic glycolysis (lactic acid
fermentation) and mitochondrial OXPHOS. Since OXPHOS produces 36 molecules of
ATP from 1 molecule of glucose when run to completion compared to only 2 molecules
from glycolysis, its efficiency makes it the preferred choice in aerobic conditions when
using glucose as an energy source. Without oxygen, cells use fermentation to regenerate
nicotinamide adenine dinucleotide (NAD+) molecules consumed during glycolysis,
resulting in either lactic acid (C3H6O3, eukaryotes) or ethanol (C2H5OH, bacteria/yeast).
However, Nobel laureate Otto Warburg noted that one of the hallmarks of cancer cells
was their seemingly peculiar penchant for generating ATP from the less-efficient aerobic
glycolysis despite normoxia, potentially for its ability to generate precursors for nucleic,
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amino and fatty acids required for the DNA replication, and protein and cell membrane
biosynthesis needed during cellular division129,130.
OXPHOS and lactic acid fermentation both begin via glycolysis – 10 separate
chemical reactions break down 1 molecule of glucose into 2 molecules of pyruvate, and
generate 2 molecules of ATP via substrate level phosphorylation. In OXPHOS, each of
the 2 molecules of pyruvate is then converted into acetyl-CoA by mitochondrial pyruvate
dehydrogenase before entering the Krebs cycle (citric acid cycle, tricarboxylic acid
cycle), where each molecule of acetyl-CoA produces 3 molecules of NADH. While still
in the mitochondrion, OXPHOS and the electron transport chain (ETC) convert the
energy stored in reduced pyridine nucleotide into ATP. The process is initiated when
NADH is oxidized at complex I, passing 2 electrons to 1 molecule of ubiquinone and
pumping 4 H+ ions from the mitochondrial matrix to the intermembrane (IM) space. The
net change in charge and ion concentration of H+ helps establish the proton motive force,
an electrochemical gradient between the matrix and the IM space. Complex II, succinate
Q-oxidoreductase, is member of both the Krebs cycle and the ETC. Succinate, one of the
intermediate products of the Krebs cycle, is oxidized to fumarate and ubiquinone is
oxidized to accept 2 electrons. Ubiquinone travels through the lipid bilayer of the
mitochondrion to complex III, where 1 electron is passed to cytochrome c, and 4 H+ ions
traverse the mitochondrial membrane into the IM space. Reduced cytochrome c then
advances to complex IV, cytochrome c oxidase. Four molecules of cytochrome c each act
as electron donors, becoming oxidized in the process. These four electrons are used to
create 2 molecules of H2O in a reaction where O2, the terminal oxygen acceptor, is
consumed. Four more H+ ions are also pumped into the IM space at this juncture to
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complete the ETC. Complex V, ATP synthase, uses the potential energy stored by the
proton motive force to create ATP from ADP and Pi. For each molecule of ATP
generated, 4 H+ ions are pumped back across the mitochondrial membrane into the matrix
(Figure 4.1). As an alternative to mitochondrial OXPHOS described above, pyruvate can
be subject to anaerobic fermentation in the absence of oxygen. In eukaryotic cells, NAD+
is regenerated, and lactic acid and CO2 are produced as byproducts. Lactic acid
production increases the number of H+ ions secreted by the cell, decreasing the pH of the
surrounding environment131. Importantly, by monitoring the changes in concentration of
molecular oxygen from the surrounding medium (oxygen consumption rate, OCR), we
can measure the amount of mitochondrial OXPHOS taking place in a given group of
cells, and by evaluating changes in pH, we can simultaneously measure glycolysis.
In addition to glucose as an energy source, cells can catabolize fatty acids and
amino acids to generate ATP. Fatty acids undergo β-oxidation (fatty acid oxidation,
FAO) in mitochondria and peroxisomes to release the energy stored in those molecules.
Because of their aliphatic nature, long chain fatty acids (>12 carbons) require activation
followed by carrier mediated transport across the outer mitochondrial membrane (OMM)
by a carnitine acyl transferase like carnitine palmitoyltransferase-1 (CPT-1) and across
the inner mitochondrial membrane (IMM) by a translocase to be oxidized. Their
hydrocarbon chains are converted into molecules of acetyl-CoA two carbons at a time,
which then feeds into the Krebs cycle and oxidative phosphorylation.
Recent work has noted the occurrence of Warburg metabolism in several
leukocytic cell types, with a general trend towards pro-inflammatory or activated
leukocytes preferring glycolysis, and anti-inflammatory cell types utilizing OXPHOS.
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Neutrophils robustly engage in aerobic glycolysis132 to engage in the pentose phosphate
pathway, an offshoot of glycolysis needed to rapidly generate the NADPH necessary for
NADPH oxidase to produce one of its main antimicrobial effector molecules, H2O2.
Stimulation of dendritic cells by TLR agonists133 or the B cells by B cell receptor
crosslinking134, induces a glycolytic shift dependent on PI3K and Akt. Within the
dendritic cell realm, aerobic glycolysis is limited to iNOS+, pro-inflammatory DCs135.
Similarly, pro-inflammatory, iNOS+ M1 macrophages depend on aerobic glycolysis136
and iNOS- regulatory M2 macrophages heavily rely on FAO137.
Stimulation of naïve and memory T cells induces a rapid change from primarily
using FAO and OXPHOS for ATP generation towards a preference for aerobic glycolysis
to support a shift from quiescence to activation in addition to actively upregulating cell
surface molecules for glucose and amino acid uptake138. The relative reliance on each
type of metabolism seems to be both a consequence of differentiation, as well as
contributing signal towards the effector lineage decision and function. Pro-inflammatory
Th1, Th2 and Th17 cells rely on glycolysis much more than their suppressor iTreg
brethren, which engage in a balanced mix of metabolic processes139. Abolition of
glycolysis by supplementing cell culture medium with 2-deoxyglucose, a competitive
inhibitor of glucose, increases iTreg development and reciprocally antagonizes Th1, Th2
and Th17 development140. Alternatively, blocking lipid metabolism by preventing
mitochondrial transfer of fatty acids with etomoxir stunts iTreg development with no
apparent effect on pro-inflammatory T cell development, whereas promoting lipid
oxidation by fatty acid supplementation to the medium has the opposite effect139. In
experiments where galactose was provided to cells instead of glucose, Th1 polarized cells
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produce less IFNγ, demonstrating the link between the glycolytic shift and effector cell
function. This deficiency could be important in creating anti-inflammatory tumor
microenvironments, where carcinogenic cells undergoing Warburg metabolism readily
deplete glucose. In fact, co-culture of T cells with tumor cells has the same IFNγ-muting
effect, which can be rescued with the supplementation of exogenous glucose141.
Therefore, the regulation of mitochondrial metabolism dynamics and their overall health
can regulate T cell fate decision and function, especially upon a T cell’s migration from a
nutritionally replete secondary lymphoid organ to a potentially deplete and hypoxic site
of inflammation.
PTEN-induced kinase 1 (PINK1) is a ubiquitously expressed serine/threonine
kinase found both at the mitochondrion and in the cytosol. In the absence of PINK1’s
kinase activity, individuals develop hereditary, early-onset Parkinson’s disease (PD)142.
In cells with healthy mitochondria, its N-terminal mitochondrial localization signal
targets PINK1 to the IMM143, where it is cleaved by the protease Presenilin Associated,
Rhomboid-Like (PARL)144,145. Though the binding of protein mitochondrial localization
sequences to the translocase of the OMM (TOM) complex is receptor-driven, the import
process is critically dependent on forces established by the mitochondrial membrane
potential (Δψm)146. Upon a decrease in Δψm, indicative of poor mitochondrial health and
reduced proton motive force, PINK1 accumulates on the surface of the individual
mitochondrion. PINK1 then recruits parkin, an E3 ubiquitin ligase which
polyubiquitinates OMM proteins and targets a mitochondrion for mitophagy, a
specialized form of mitochondrial autophagy which specifically culls damaged
mitochondria for recycling147. In addition, PINK1 can exist in the cytoplasm, where it
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activates the PI3K/Akt/mTOR pathway148,149. Because pro and anti-inflammatory T cell
subsets have different energy requirements, and T cell fate decisions can be altered by
manipulating its nutritional milieu, we wondered how the lack of functional PINK1 as in
some PD patients would affect T cell activation, differentiation and function. By using a
PINK1 knockout mouse model, we reveal that an impairment in T cell activation,
OXPHOS and IL-2 signaling in iTreg polarizing conditions results in the generation of
FoxP3+ iTregs without in vitro suppressor function.
4.2

Results
4.2.1

Absence of PINK1 attenuates Akt activation in response to TCR

stimulation
Our collaborators in the laboratory of Dr. Hansruedi Büeler demonstrated
defective Akt signaling in cells lacking PINK1 downstream of the insulin and IGF-1
pathways69, which show similarity to the TCR signaling pathway150. When we
crosslinked the TCRs of PINK1-/- peripheral lymph node (PLN) T cells, both Western
blot (Figure 4.2A) and flow cytometry (Figure 4.2B/C) showed reduced S473-Akt
phosphorylation versus their wild type counterparts. Because β- selection of αβ
lymphocytes requires Akt151, we immunophenotyped murine thymocytes to look for
developmental defects, and surprisingly found normal numbers and compositions of
precursor T cell pools in knockout mice (Figure 4.3), potentially due to functional
compensation by other Akt isoforms152 or the higher levels of mitochondrial content in
thymocytes153, rendering the cells resistant to impaired mitophagy.
4.2.2

PINK1 is required for full early activation and proliferation of T cells
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Deficient TCR signaling in cells lacking PINK1 foreshadowed effects on ensuing
proliferation and activation. Indeed, stimulation of PINK1-/- T cells with α-CD3/α-CD28
resulted in few proliferating cells (Figure 4.4A) and low expression of the early activation
markers CD69 and CD25 (Figure 4.4B/C). These changes were not associated with
differences in production of IL-2 downstream of CD28 signaling, as synthesis was
similar between groups (Figure 4.4D). When we analyzed the integrity of the IL-2
signaling pathway, phosphorylation of STAT5154, pS473-Akt149, pT308-Akt149 and
FOXO1155, but not GSK-3β was impaired, and GLUT1156 expression was reduced
(Figure 4.4E), indicating that some, but not all of the conventional Akt pathway and
mTORC2 are less active. Since the PI3K/Akt/mTOR axis is a known regulator of
mitochondrial metabolism157, we determined Δψm by measuring the fluorescence
intensity of TMRE, a positively charged, lipophilic dye that accumulates in mitochondria
proportionally to its Δψm158. In most non-lymphoid cells lacking PINK1 or expressing a
non-cleavable mutant form, basal levels of Δψm are decreased compared with wild type
cells144,159–161. Surprisingly, unstimulated T cells from PINK1-/- mice had similar levels of
TMRE fluorescence across central memory, effector memory and naïve subsets of both
CD4+ and CD8+ T cells. However, when activated with α-CD3 + IL-2, but not α-CD3 +
α-CD28, membrane potential was decreased in cells lacking PINK1 (Figure 4.4F).
Though TMRE fluorescence is a fine indicator of mitochondrial health and
fidelity, it does not directly measure a cell’s metabolic prowess. Based on the principles
that mitochondrial OXPHOS consumes oxygen from, and glycolysis deposits hydrogen
ions into, the surrounding medium, we used a bioanalyzer to measure extracellular flux in
real-time with O2 and H+ responsive fluorophores as follows (Figure 4.5A/B). First, three
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initial measurements determined the baseline OCR. The bioanalyzer then injected
oligomycin into each of the wells, plugging the F0 subunit of complex V, and
distinguishing the contribution of ATP synthesis to the basal oxygen consumption versus
the contribution of proton leak across the IMM. Next, the protonophore FCCP allowed
H+ ions to freely pass through the IMM, inducing a maximal OCR. By subtracting the
baseline OCR from the maximal OCR, we can calculate the spare respiratory capacity
(SRC): the reserve ATP producing potential a cell has, which is related to its number of
mitochondria, the relative function of its ETC and OXPHOS components and its ability
to acquire and deliver energy sources to the correct subcellular location. Following
FCCP, we injected etomoxir, a CPT1 inhibitor that isolates the contribution of fatty acid
versus non-fatty acid oxidation to maximal respiratory capacity. Finally, a combination of
rotenone and antimycin A were added to block complexes I and III of the ETC
respectively, which stops H+ pumping to the IM space. The OCR at this point and all
points past represents the non-mitochondrial oxygen consumption.
The mitochondrial flux of both PINK1 sufficient and deficient T cells activated
overnight with α-CD3 and α-CD28 were statistically indistinguishable, indicating normal
operation of the CD28 co-stimulatory pathway despite the loss of a protein which
promotes Akt phosphorylation. Conversely, IL-2 treatment with α-CD3 in PINK1-/- cells
reveals a metabolic defect, with a clear decrease in the values of basal respiration, oxygen
consumption due to ATP production, maximal respiration and spare respiratory capacity.
In segment D of the analysis where FCCP allows H+ ions to freely traverse the IMM but
fatty acid transfer into the mitochondrion is blocked by the CPT-1 inhibitor etomoxir, the
deficit is shown to be from non-fatty acid energy sources for OXPHOS (Figure 4.5C),
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potentially related to decreased expression of the Akt-responsive gene GLUT1 (Figure
4.4E). Insufficient glucose acquisition could also be the cause of reduced basal ECAR
levels seen in the same cells (figure 4.5D). Disruption of mitochondrial OXPHOS via
reduced Δψm could prevent the ability of a cell to meet certain metabolic checkpoints157,
diverting cellular fate decisions or inhibiting effector function.
4.2.3

Induced regulatory T cell development and function requires PINK1

We and others have demonstrated the crucial role of the Akt pathway in the
conversion of conventional T cells into suppressor iTregs162–164. Since decreased IL-2
receptor and Akt signaling oppose each other in the decision of a T cell to acquire an
iTreg phenotype165, we asked how PINK1-/- T cells would react to signals from iTreg
polarizing conditions. Knockout cells first exhibited a delay in the surface expression of
CD25 and CTLA-4, yet never faltered in their expression of FoxP3 (Figure 4.6A). In
association with this outcome, fewer PINK1-/-cells proliferated, which is of particular
interest, as the acquisition of suppressor ability is associated with multiple rounds of cell
division (Figure 4.6B). When we measured the suppressor ability of sorted, PINK1
sufficient or deficient iTregs (Figure 4.6C/D), only wild type iTregs were able to dampen
the proliferation of co-cultured, CFSE labeled target cells, indicating an uncoupling of
FoxP3 expression and suppressor function in vitro (Figure 4.6E/F). The deletion of
PINK1 seemed to only affect the acquisition of anti-inflammatory activity, as Th17inducing medium could induce the simultaneous expression of both RORγT and IL-17 in
those cells (Figure 4.6G) despite reduced GLUT1 expression (Figure 4.4E) and
glycolysis rate (Figure 4.4I).
4.3

Discussion
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With the recent appreciation for the effect that metabolic checkpoints and
metabolic control of effector T cell development and function, the examination of T cell
responses in cells lacking a key regulator of both Akt and mitophagy such as PINK1 was
certainly warranted, especially as mutations in PINK1 are associated with familial, early
onset PD. Here, we show that PINK1 aids in the activation of T cells and the acquisition
of suppressor function in iTregs related to Akt, IL-2 and metabolism.
The dual nature of PINK1’s localization suggests that the protein may play an
active role in adapting a cell’s response to energetic cues and TCR stimulation. As Akt
was first implicated in oncogenesis, likewise has the cytoplasmic localization and
increased expression of PINK1 been implicated in cancerous cells166,167, an instance of
uncontrolled cell division. Though we have shown above that PINK1 is important in full
activation of Akt, this effect is most likely indirect, as Akt has yet to be added to the
growing list of PINK1 phosphorylation targets. However, its residence in the cytoplasm
and availability to influence Akt activation status relies on autophosphorylation, as kinase
dead PINK1168 mutants localize to the cytoplasm. PINK1 knockout T cells also show
reduced the activation of mTOR as indicated by reduced phosphorylation of Akt at S473,
a target of mTORC247, and extrapolated from the reduction of p-S308. Indeed, cells
lacking PINK1 have reduced phosphorylation of ribosomal protein S6149, the target of S6
kinase whose phosphorylation is frequently used to gauge mTOR function. Reduced
mTOR signaling attenuates transcription and translation by modulating its targets 4E-BP1
and S6 kinase, which could explain the delayed surface expression of CD25 and CD69
reported above.
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At the mitochondrion, PINK1 specifically targets mitochondria with reduced
Δψm for recycling via mitophagy, increasing overall mitochondrial health. We show, in
agreement with many other cell types of PINK1 deficient cells, that T cells lacking
PINK1 have decreased Δψm after stimulation with α-CD3/IL-2 (Figure 4.4F). What’s not
clear though, is whether this decrease is related to the quiescent nature of resting cells
versus their rapidly dividing, stimulated counterparts, or reflects mitophagy as an
important part of the T cell activation process. Naïve CD8+ T cells increase their
mitochondrial mass during the expansion/contraction phases of T cell activation such that
memory T cells have an increased SRC dependent on IL-15 and FAO. This increased
capacity for OXPHOS contributes to the increased speed of secondary activation169, a
hallmark of T cell memory, and demonstrates the effects of mitochondrial function on T
cell phenotype. Though we did not see an increase in SRC upon activation even in wild
type CD4+ T cells (data not shown), potentially due to our not specifically inducing T cell
memory, there was a reduction in Δψm in IL-2 activated PINK1-/- cells, which could
indicate that the inability to recycle old mitochondria into new mitochondria during
activation.
The PI3K/Akt/mTOR pathway engages in crosstalk with other pathways to
coordinate the cellular response to changes in the extracellular environment. The function
of AMP-activated protein kinase (AMPK), a negative regulator of mTOR both directly170
and indirectly171, is modulated by fluctuations in intracellular AMP/ATP concentration or
perturbations in normoxia. ATP, ADP and AMP bind to the γ regulatory subunit of
AMPK to alter its activation. In cells with a high AMP/ATP ratio, and thus displaying
energetic deficiency, AMPK is found in its phosphorylated, active form and vice versa.
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By inhibiting mTOR at this state, AMPK is able to restrain protein synthesis in times of
malnutrition or starvation. Oligomycin treatment of PINK1 knockdown cells caused a
rapid decrease in Δψm159, indicating that the mitochondrial membrane potential was
maintained by complex V running in reverse and hydrolyzing ATP. The increased
AMP/ATP ratio and AMPK activation likely to result from this action provides an
alternative, mitochondrial explanation for the PI3K/Akt/mTOR pathway inhibition seen
above. An investigation into intracellular signaling in PINK1 deficient cells in response
to extracellular oxygen and nutrient availability would be of interest, particularly as the
AMPK activator metformin is currently prescribed to treat hyperinsulinemia, having
effects on mTORC1 similar to rapamycin, which could include skewing the T cell
repertoire towards iTreg development172. Following, T cells lacking AMPK have
increased glycolytic levels and IFNγ production is bolstered173.
Another activation signal downstream of TCR activation not investigated here
involves the transient increase in intracellular calcium concentration174. Membrane
depolarization of WT neurons induces an increase in cytosolic and mitochondrial
calcium. In PINK1 KO cells, this increase is accompanied by a subsequent loss of
Δψm159. Notably, T cell and B cell receptor stimulation leads to a similar increase in
cytosolic calcium levels which is sustained by mitochondrial action and dependent on
Δψm175. It remains an interesting possibility that part of the effect of PINK1 loss is by
disrupting the second messenger signaling role of Ca+2 in its activation of NFAT, NF-κB,
CRAC channels, etc.176. Since the intracellular calcium spike is differentially regulated in
iTregs162, PINK1 might be necessary for T cell fate decisions downstream of
mitochondrial calcium regulation.
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The effect of PINK1 loss had variable effect on metabolism following stimulation
with α-CD28 and IL-2 despite a deficiency in Akt phosphorylation in both pathways.
Since CD28 stimulation induces IL-2 secretion, it is presumed that the IL-2 pathway is
activated in cells undergoing both treatments, so that the only difference between the
groups was in the IL-2 cultured cells lacking the strong stimulation of CD28 and the
whole of its downstream elements177. Though α-CD3 with IL-2 and TGF-β is sufficient to
induce FoxP3 in wild type and PINK1 cells, levels of OXPHOS are not sufficient in
PINK1 cells to endow suppressor activity, supporting the hypothesis that metabolic
checkpoints control T cell differentiation.
Although others have suggested links between PINK1 and type 2 diabetes178,
cancer166,167 and psychiatric dysfunction179, there exists no epidemiologic correlation
between PINK1 loss and immune dysregulation, potentially related to the relative rarity
of PINK1 mutations (1%-9% of early onset PD)180 or to concomitant effects on proinflammatory cell activation in vivo as seen in Raptor-/- mice20. The failure of PINK1-/mice to develop an autoimmune syndrome could be the result of incomplete elimination
of suppressor function in vivo or the normal development of nTregs. However, we would
expect these mice to have an exacerbated reaction to a subsequent inflammatory
challenge. Indeed, the effect of PINK1 loss on T cell subset differentiation via type of
metabolism or mTORC2 activation52,148 could each skew the T cell response52,139,
resulting in inappropriate immune responses or autoimmunity. Particular to our own lab’s
interest in gut homeostasis, we would expect that these immunodysregulations to affect
the microbiotal composition and have far reaching effects on obesity181 as well as
peripheral182 or enteric inflammation183.
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Several studies have shown abnormalities in peripheral T cell populations in
sporadic PD184–186: CD4+ and CD8+ T cell infiltrates are present in the post-mortem
human Parkinsonian brain and CD4+ T cells directly contribute to dopaminergic neuron
loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD.
Yet, the low frequency of lymphocytes behind the blood-brain-barrier during noninflammatory conditions is inconsistent with the contribution of T cells in disease
initiation in PD. Rather, calcium induced cell death of dopaminergic neurons during
disease159 activates resident microglia to secrete cytokines, inviting T cell infiltration and
potentially provoking disease progression. Mice with reduced numbers of CD4+ CD25+
Tregs showed increased microgliosis and dopaminergic neuron death in response to
MPTP, whereas adoptive transfer of Tregs protected against neuron loss187. Since PD is
not yet curable, and prescribed drugs focus on the management of symptoms, immune
system modulation could be a novel, unexplored therapeutic avenue through which
disease progression can be halted. Indeed, TZD treatment blocks iNOS expression to
protect from a mouse model of PD188 , and retinoic acid has similar iNOS-inhibiting
effects in microglia189. Mitochondrial dysfunction has been a focus of PD related research
since the discovery that MPTP, a complex I inhibitor, caused substantia nigra cell death
and PD-like symptoms in humans. Since mitochondrial dysfunction is not only present in
PINK1 deficiency, but also a hallmark of all forms of sporadic PD190, metabolic defects
may likewise account for altered T cell subpopulations and function in sporadic PD. If so,
elucidating T cell function in the absence of PINK1 may also help to unravel the role of T
cells in the progression of sporadic PD. Further investigation of T cell function in carriers
of PINK1 mutations may be warranted in parallel with studies in PINK1-deficient mice,
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especially as mutations involving different domains of PINK1 have been discovered, and
which might affect only some of PINK1’s full suite of functions.
A model based on the results in this chapter can be found in Figure 4.7. During
quiescence, PINK1 associates with both healthy and damaged mitochondria. By
accumulating on the surface of mitochondria with low Δψm, it recruits the machinery
needed for mitophagy to maintain homeostatic turnover of damaged organelles. Healthy
mitochondria import PINK1 for cleavage, leaving a stable, cytosolic cleavage product.
Experiments re-constituting PINK1 knockout T cells with an uncleavable mutant of the
protein will unravel the function of this byproduct. If the truncated PINK1 retains its
ability to aid in Akt/mTOR activation and upregulation of OXPHOS, it would be
interesting to hypothesize its role in signaling to the cell that mitochondria are healthy
and the cell is prepared to grow and divide. Upon TCR crosslinking with CD28 and IL-2
pathway signaling, prevention of PINK1 autophosphorylation and subsequent
cytoplasmic location could support the PI3K/Akt/mTOR pathway and OXPHOS to meet
the cell’s new energetic demands. Meanwhile, its absence from the mitochondrion would
halt mitophagy and selective ETC protein turnover but not mitochondrial biogenesis,
resulting in a net increase in mitochondrial mass and OXPHOS. Future studies
complementing PINK1-/- cells by transfecting expression vectors for wild type or ΔNterminus PINK1 protein which accumulates in the cytoplasm168 will aid in identifying
explicitly cytoplasmic function.
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Figure 4.1 Schematic of the electron transport chain and oxidative phosphorylation. The
electron transport chain drives H+ ions across the IM into the IM space to establish the
proton motive force needed for oxidative phosphorylation at Complex V. Figure created
by Dr. Timothy Vickers (Washington University in St. Louis) and released into the public
domain.
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Figure 4.2 TCR crosslinking of peripheral CD4+ T cells requires PINK1 for optimal Akt
activation. (A) Western blot comparison of activated Akt (pS473-Akt) and total Akt in
peripheral LNs cells after CD3/CD28 stimulation. Activated LAT (pY191−LAT) was
included as a control to demonstrate equal TCR activation. (B) Percent of cells with
activated Akt after stimulating peripheral LNs cells for 3 min with α-CD3 and α-CD28
antibodies. Cells were first gated for lymphocytes by forward and side scatter before
CD4+ T cells were selected. Data shown as mean + SD. (C) Representative histogram of
data in B. Mean fluorescence intensity (MFI) is indicated to right of the plot. n = 4
individual mice and are representative of three independent experiments.
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Figure 4.3 Flow cytometry analysis of thymus cells from wild type and PINK1-/- mice.
Left contour plots represent all cells, right contour plot has been gated solely on the
double negative thymocytes to assess populations of DN1-4 T cell precursors, n = 3
individual mice.
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Figure 4.4 Reduced activation of CD4+ T cells in PINK1−/− mice. (A) Percentages of
proliferating CD4+ LN T cells from PINK1−/− mice were assessed by Ki-67 expression
after 48h of α-CD3/α-CD28 stimulation (left). (Naive = CD62L+ CD44−; Tcm (centralmemory T cells) = CD62L+ CD44+; Tem (effector-memory T cells) = CD62L− CD44+)
Representative histogram (right). (B) MFI of surface CD69 on CD4+ T cells activated as
in Figure 4.4A for the indicated time points. (C) Percentage of CD25+ cells of CD4+ T
cells stimulated as in Figure 4.4A. (D) Intracellular cytokine staining of T cells after 48h
α-CD3/α-CD28 stimulation. Cells were then incubated with GolgiStop, PMA and
ionomycin for 5 hours before flow cytometry analysis (n = 6 individual mice; mean +/SD). (E) Western blot of components of the IL-2 and Akt-signaling pathways after
culture with α-CD3 and IL-2 for 48h. (F) Δψm was measured by flow cytometric analysis
of TMRE after 48h of the indicated stimulus (n = 4 individual mice; mean + SD). A–C,
E, F: Data shown as mean + SD pooled from at least three independent experiments, n =
6 individual mice. D: Data are representative of two independent experiments, n = 6
individual mice. *p < 0.05; two-tailed Student’s t-test.
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Figure 4.5 Extracellular flux analysis of activated CD4+ T cells reveals metabolic
deficiencies downstream of IL-2 pathway (A) Mitochondrial OXPHOS was monitored by
calculating the OCR via the depletion of O2 from the surrounding medium in CD4+ T
cells treated for 48h with either α-CD3 + IL-2 or α-CD3 + α-CD28. Oligomycin (1 μM),
FCCP (1.5 μM), etomoxir (200 μM) or rotenone/antimycin A (1 μM each) were added at
the time points indicated by vertical bars. (n = 4 individual mice; mean +/- SEM). (B)
Derived parameters for evaluating OXPHOS are as follows: Basal resp.: A-E; ATP Prod.:
A-B; max resp.: C-E; spare respiratory capacity (SRC): C-A; fatty acid (FA) resp.: C-D;
Non-FA resp.: D-E. (C) Ratio of OCR between cells cultured with α-CD28 or IL-2 for
48h as a direct measure of oxidative phosphorylation, summary of experiment in 4.5B;
a.u. = arbitrary units. (D) Baseline extracellular acidification rate (ECAR) from 4.5B, n =
4 individual mice; mean + SD. Data are representative of two independent experiments.
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Figure 4.6 Reduced suppressor activity in PINK1−/− iTreg cells. (A) Flow cytometric
analysis of CD4+ FoxP3+ T cells and their expression of CD25 and CTLA-4 at days 3 and
5 of culture in iTreg polarizing conditions. (B) Percentage of CD4+ T cells having
undergone more than three rounds of proliferation after culture in iTreg medium as
assessed by CFSE dilution (left). Average number of divisions undergone per cell
(division index) is shown in the right panel. (C) Phenotype of cells used in suppressor
assay. Contour plots shapes of CD25+ look slightly different in wild type and PINK1-/CD4+ T cells although they show equivalent percentage of cells. (D) Sorted populations
had similar mean fluorescence of CD25 (bottom) and CD25hi cells. (E) CFSE labeled
target cells at a ratio of 3:1 with either CD25hi iTreg cells or CD25− T cells were co-
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cultured for 5 days with α-CD3/α-CD28 stimulation. Representative histograms of the
suppressor assay. (F) Graph representing the percentage of target cells that underwent
cell division in 4.6E. Data are shown as mean + SD pooled from three independent
experiments. *p < 0.05; two-tailed Student’s t-test. (G) Representative flow cytometry
plot of CD4+ T cells cultured in Th17 polarizing conditions for 6 days (left). Bar graph of
IL-17 expression (right). Data represent mean + SD for n = 6 individual mice.
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Figure 4.7 Chapter 4 model. During a quiescent state, PINK1 (green) associates with
both healthy and damaged mitochondria. Healthy mitochondria import and cleave PINK1
to leave a stable cytosolic cleavage product with unknown qualities, while damaged
mitochondria are destined for mitophagy to recycle cellular components. When the TCR
is activated with IL-2 and CD28 stimulation, PINK1 relocates to the cytosol where it is
able to enhance glycolysis and glucose uptake by fostering the activation of the
Akt/mTOR pathway. Meanwhile, damaged mitochondria without PINK1 escape
mitophagy.

Copyright © Gavin Isaac Ellis 2013
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Chapter 5: Discussion
5.1 The activities of PPARγ/RDH10 and PINK1 are integrated through Akt/mTOR
and metabolism
Over the course of this dissertation, we have shown that PPARγ is necessary for
human iTreg development, and that part of its mechanism of action is by directly binding
to RDH10 to endow T cells the ability to endogenously metabolize retinol, and that
PINK1 contributes to the acquisition of suppressor activity in FoxP3+ iTregs by aiding in
T cell activation, boosting non-fatty acid OXPHOS and maintaining healthy levels of
Δψm. Both the PPARγ/RDH10 and PINK1 pathways help a T cell to sense nutrients in
the environment, and are pathways integrated through the PI3K/Akt/mTOR axis and
effects on mitochondrial metabolism towards subsequent iTreg differentiation and
acquisition of suppressor function.
Several hypotheses exist as to the mechanism of action of retinoids in the
bolstering of iTreg population which include direct antagonism of RORγT191, the
enhancement of Smad3 activity192, the downregulation of the IL-6 and IL-23 receptors
needed for Th17 development192, or by binding of RAR/RXR to a RARE in the CNS1
region of Foxp3 and subsequently interfering with STAT6-mediated deacetylation193.
These mechanisms more than likely synergize as part of an ATRA program, a component
of which could be through the modification of metabolism. Indeed, the treatment of
isolated mitochondria with retinol is sufficient to increase OXPHOS by increasing
activity of the pyruvate dehydrogenase complex which generates acetyl-CoA for the
Krebs cycle194 and the ATRA-induced differentiation of SH-SY5Y human neuroblastoma
cells increases SRC and level of OXPHOS195. Therefore, part of the iTreg boosting
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mechanism of retinoids could be via the increase in OXPHOS in the presence of RARα
stimulation. Because of RDH10’s localization in the MAM, we predict that its
metabolism of retinol affects mitochondrial dynamics.
Similarly, PPARγ interacts in the same arena as PINK1 via its negative regulation
by Akt196. As the master transcriptional regulator of adipocyte differentiation, deficiency
of PPARγ is also associated with metabolic disorders and increased free fatty acid
levels197, reducing their assembly into adipocytes for storage. In PINK1 knockout mice,
the only overt phenotype seen is a consistent increase in body mass across both
genders149, indicative of a metabolic disorder, and PINK1 and PPARγ mutations are both
associated with type 2 diabetes in humans. Since PPARγ controls the levels of
unincorporated fatty acids, it regulates the ability of mitochondria to undergo FAO,
critical for iTreg differentiation.
These actions of PPARγ and retinoids integrate with PINK1 through metabolism
as part of a nutrient sensing system that ensures that a differentiating T cell has the
mitochondrial function and fuel sources to pass through metabolic checkpoints. Future
work determining the rates of OXPHOS and glycolysis in RSG or retinoid treated T cells
in wild type, PINK1 or Akt deficient mice will be of value in investigating the hypothesis
that part of the iTreg-inducing mechanism of the PPARγ and retinoid pathways is
through modulating OXPHOS. In parallel, the same experiments should be performed on
sorted immune cells from isolated from human disease states, especially IBD, to
determine if a metabolic component of disease etiology or progression exists, identifying
a population of patients which could benefit from pharmacological modulation of
metabolism, including a newly-discovered PINK1 enhancer molecule198.
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Contemporary literature seems to be binary in its description of iTreg function
(i.e. suppresses T cell proliferation and ameliorates disease, or fails to), and does very
little to sort out the multitudes of potential anti-inflammatory mechanisms. In a disease
state, the loss of peripheral tolerance could be attributed to (1) reduced Treg suppressor
function(s), (2) fewer Tregs at site of immunopathology or (3) resistance of proinflammatory cells to Treg suppression. The complexity could be compounded, as
disease etiology and progression can be combinatorial, synergistic and can vary between
individuals despite a similar diagnosis. In chapter 4, the uncoupling of FoxP3 expression
and the ability to suppress bystander T cell proliferation in FoxP3+ PINK1-/- Tregs should
not represent a complete failure of suppressor ability, but rather indicates that the entire
suite of suppressor mechanisms under the transcriptional program of FoxP3 has not been
engaged as a result of PI3K/Akt/mTOR signaling and metabolic deficiencies. iTreg
function in other in vitro suppressor assays (e.g. ability to suppress DC activation) or in
vivo models of autoimmunity could remain fully operational to wild type levels, and such
experiments are needed to fully characterize Akt dependent versus independent
suppressor functions of iTregs.
5.2

Overall significance
The fundamental impetus for conducting the research presented here is to improve

our understanding of human regulatory T cell biology, so that it may be translated into
novel therapeutics for pathology related to immune dysfunction. Though modulation of
iTreg populations has shown prophylactic and therapeutic efficacy in murine models of
immunopathology and autoimmunity, the translation of these protocols to the clinic has
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not yet been as successful because of our incomplete understanding of human iTreg
biology.
Two strategies for iTreg therapy might be used, either ex vivo or in vivo treatment,
each with its own benefits and drawbacks. With ex vivo therapy, a patient’s blood is
drawn, T cells are isolated, cultured in appropriate medium, sorted and re-infused.
Notwithstanding the high cost of such a procedure (see: autologous dendritic cell
vaccines), we as of yet do not have a panel of cell surface markers which can definitively
identify a pure population of suppressor T cells. Though FoxP3 does identify pure Tregs
in murine populations, activated effector T cells in humans transiently upregulate FoxP3,
and because FoxP3 is an intracellular protein, its detection requires permeabilization of a
cell, resulting in its death. Ex vivo handling also requires a strict chain of custody to
ensure a patient receives his own blood product, sufficient sterility and good
manufacturing practices. The re-infusion of pro-inflammatory effector cells even at
scarce levels could amplify the immune response and exacerbate disease. Handling of the
cells does provide the opportunity for genetic manipulation – perhaps to correct a
defective, disease-causing pathway, or inserting a suicide vector which instructs cells to
apoptose upon FoxP3 withdrawal – and avoids the side effects of systemic drug
administration. in vivo treatment involves oral, injectable or suppository drugs directly
into the body. Its most infamous application occurred in the trial of TGN1412, a
superagonist antibody directed against the costimulation receptor CD28. Though
efficacious in rodent and simian trials, injection of TGN1412 into human recipients could
not target Treg populations with any specificity, and thus rapidly expanded proinflammatory T cells into a near-fatal cytokine storm199. The advantage of in vivo
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treatment though, is the ease at which a patient can self-medicate, practically able to stay
on one set of medications for perpetuity. Regardless of whichever therapeutic modality
emerges as the clinician’s choice, the control of Treg function must be impeccably tuned,
as an over-exuberant response will reduce peripheral immunosurveillance and result in an
immunodeficient state. Successful pathogens and tumors have been known to harness this
facet of Treg biology via manipulation of their own microenvironments with the secretion
of TGF-β, retinoic acid or other pro-Treg molecules.
In the pro-inflammatory context of gut inflammation, PPARγ stimulation is part
of the mechanism of action of the oft-prescribed IBD drug 5-aminosalicyclic acid (5ASA)200, and high vitamin A therapy also has anti-colitic effects100. Based on our work in
chapter 3, we believe that these pathways are connected through RDH10 activation and in
dendritic and T cells, and that this link can be exploited therapeutically. The
supplementation of the diet with oral retinyl esters would boost the efficacy of 5-ASA via
its iTreg inducing effects. Since the majority of T cells in the pathogenic and nonpathogenic gut are effector and memory T cells that remain inert towards ATRA, PPARγ
stimulation has the potential to upregulate RDH10 and RARα to enable ATRA
responsiveness. In addition, modulation of specific mTORCs could act in the specific
suppression of Th1 responses in Crohn’s disease or Th2 immunity in ulcerative colitis.
5.3

Conclusion
The work described here highlights the PI3K/Akt/mTOR pathway as a molecular

hub for the integration of extracellular signals and ensuing T cell fate decisions in the
control of iTreg differentiation and function. As the acquisition of iTreg phenotype
occurs in a two-step process – cells undergo an initial proliferative burst followed by a
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period of differentiation – the kinetics of molecular signaling must differ to support each
phase, which could be regulated by Akt and PPARγ. In the initial 24 hours after TCR
stimulation, the PI3K/Akt/mTOR pathway is very active, executing the switch from
OXPHOS to glycolysis, rapidly increasing cell growth and producing biomolecules for
new cell synthesis. Although RARα and PPARγ ligands could be available to the cell,
active Akt suppresses RAR (via direct phosphorylation201) and PPARγ (via
phosphorylation of its co-activator PGC-α196). Following the ensuing cellular divisions,
TCR stimulation is detrimental to iTreg differentiation and expression of FoxP3; T cells
stimulated in vitro for 54 hours do not express FoxP3, while those that had TCR
stimulation withdrawn after 18 hours see a robust upregulation165,202. Following, the
addition of PI3K, Akt or mTOR antagonist to the culture medium during the later 36
hours greatly increases iTreg differentiation, mimicking the cessation of CD3 and CD28
signaling165. The later release of Akt from activation could not only catalyze the switch
back to OXPHOS, but would also derepress RARα and PPARγ, allowing for their proiTreg signals in addition to the maintenance of high levels of OXPHOS.
We also confirm in a second system (Raptor knockout being the first20) that
FoxP3 expression in the absence of functional Akt/mTOR and mitochondrial ATP
metabolism is not sufficient to endow suppressor function in murine Tregs, where FoxP3
was thought to be sufficient. Upon TCR stimulation, PINK1 is involved in the
phosphorylation of Akt, increasing the uptake of glucose, early T cell activation,
OXPHOS and glycolysis, allowing the developing T cell to reach molecular checkpoints
that regulate the immune response. Though an increase in OXPHOS is part of the iTreg
gene regulatory program downstream of FoxP3, interfering mutations downstream of
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FoxP3 or the migration of a T cell to a hypoxic or nutrient poor microenvironment could
prevent the acquisition of suppressor function. Though this metabolic checkpoint
provides an additional regulatory mechanism to control T cell function, its dysregulation
represents a further source for immunological dysregulation. Overall, our work provides
a new molecular framework on which to monitor for deficiencies in autoimmune disease,
and to base new therapeutics for the creation of stable, effective, properly trafficked
iTregs in IBD or PD.

Copyright © Gavin Isaac Ellis 2013
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